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                                                                                                                  SUMMARY 
El Síndrome de hiperestimulación ovárica (SHO) es una complicación iatrogénica 
provocada por el uso de gonadotropina coriónica humana (hCG) para la inducción 
de la ovulación. La sobreexpresión ovárica del Vascular Endothelial Grown Factor 
(VEGF) produce un aumento de la angiogénesis y de la permeabilidad vascular 
(PV), síntomas que desencadenan el SHO. Pese a su gravedad, los tratamientos 
del SHO en mujeres sometidas a técnicas de reproducción asistida (TRA) se han 
limitado a cuidados paliativos, al desconocer su fisiopatología. Estudios previos 
realizados por nuestro grupo describieron la presencia del receptor D2 de 
dopamina (D2) en ovario y observaron que la activación de este receptor inhibe la 
PV, sin afectar a la angiogénesis, en ratas hiperstimuladas (Gómez R et al., 2006). 
Estas observaciones se confirmaron en humanos con mujeres con riesgo de sufrir 
SHO (Álvarez C, et al., 2007), en las que se describió también la expresión de D2 
en las células de la granulosa (CG). En base a las evidencias científicas 
publicadas, el presente trabajo de tesis doctoral hipotetiza que los D2 agonistas 
(D2-ag) puede ejercer un efecto inhibitorio en la producción de VEGF por las CG y 
con ello disminuir la PV ovárica. Esta hipótesis sugiere la existencia de un sistema 
dopaminérgico en el ovario, el cual determina la susceptibilidad de cada mujer a 
los cambios de PV a través del sistema de regulación VEGF/VEGFR2, y con ello a 
desarrollar patologías de ovario dependientes, tales como SHO. Por todo ello, se 
postula que mujeres con riesgo de desarrollar el SHO, como son mujeres con 
Síndrome de Ovario Poliquístico (SOP), pueden presentar un tono dopaminérgico 
desregulado y/o disfuncional.   
Con el propósito de corroborar esta hipótesis se pretendió identificar las 
poblaciones celulares del ovario que expresan D2 y aislarlas mediante un método 
que nos permitiera obtener el mayor número de células puras, con el fin de 
cultivarlas in vitro.  En segundo lugar, se pretendió determinar la relación entre 
sistema dopaminérgico (dopamina (Dp)/D2) y sistema VEGF/VEGFR2 en 
condiciones fisiológicas y patológicas (SOP), con el fin de determinar si existen 
diferencias entre ellas. 
SUMMARY 
 
De los métodos de aislamiento de GC analizados, el método de aislamiento 
mediante filtros fue el que ofreció mayor efectividad en cuanto a la cantidad de 
células recuperadas, sin comprometer significativamente a la pureza.  
Una vez aisladas, estas células fueron cultivadas in vitro con el fin de estudiar la 
relación entre sistema dopaminérgico (Dp/D2) y sistema VEGF/VEGFR2. Los 
resultados de dicho estudio demostraron que la secreción del VEGF fue inhibida 
por el D2-ag de una forma dosis-dependiente. Así mismo, se evidenció que el D2-
ag estaba mediado por su receptor D2. Dicha expresión del receptor D2 se 
correlaciona con la inhibición de VEGF, existiendo una relación dosis-dependiente 
entre la cantidad de D2 expresada y el grado de inhibición del VEGF observado. 
Finalmente, al comparar el tono dopaminérgico y sistema VEGF/VEGFR2 en 
condiciones fisiológicas y patológicas (SOP), se observó una disminución en la 
expresión de D2 y un aumento en la vascularización en las pacientes SOP. 
Además, observamos en estas pacientes, un metabolismo acelerado de la Dp y un 
porcentaje de inhibición del VEGF disminuido en comparación con pacientes 
sanas. 
Con todo ello, podemos concluir en este trabajo de tesis doctoral que el D2-ag 
inhibe la secreción de VEGF mediante la activación de D2 de manera dosis 
dependiente, tanto en condiciones fisiológicas como patológicas. Sin embargo, en 
condiciones  patológicas (SOP) la administración de D2-ag es menos efectiva en 
prevenir el SHO debido a que dichas pacientes presentan un metabolismo 
acelerado de la Dp junto con un tono dopaminérgico desregulado, el cual provoca 
que el D2 presente una baja eficiencia en inhibir la secreción del VEGF cuando es 
activado por D2-ag. Puesto que dicha capacidad del D2 en inhibir el VEGF es 
dosis-dependiente, un aumento de la concentración intraovárica de D2-ag podría 
ser suficiente para prevenir el SHO. 
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1. INTRODUCTION 
 
 
1.1. OVARIAN HYPERSTIMULATION SYNDROME BACKGROUND 
In the second half of the twentieth century, the management of human infertility, 
and the development of advanced assisted reproduction techniques (ART) by 
modern medicine has progressed considerably. Ovarian stimulation, used in order 
to obtain the highest possible number of oocytes, has been key to such treatments. 
The use of ovulation-inducing drugs, such as gonadotropin, is highly effective in 
ovarian stimulation and was a breakthrough for these techniques. However, 
although these techniques bring benefits, we must also acknowledge the possibility 
of complications, which in some cases are associated with the appearance of 
ovarian hyperstimulation syndrome (OHSS). 
OHSS has been known of since 1943, when gonadotropins were first used to 
induce ovulation (Rydberg E, et al., 1943, Davis E, et al., 1944), and at that time 
the disease was referred to as “syndrome d’hyperluteinisation massive des 
ovaires” in French. The first fatal cases were described in 1951 (Altirriba E, et al., 
1961). In 1957, Le Dall described this ‘syndrome’ in his thesis and subsequently 
published acute cases in which laparotomy and unilateral ovariectomy were 
required (Le Dall R, 1957). Although, the term ‘ovarian hyperstimulation syndrome’ 
was not found in the literature until 1968 (Mingeot R, et al, 1968), based on the 
clinical and laboratory parameters described by many authors (Rabau E, et al., 
1967, Schenker J. and Weinstein D, 1978; Golan A, et al., 1989; Navot D, et al., 
1992; Whelan I. and Vlahos N, 2000; Aboulghar M and Mansour, 2003) and 
despite the different terminology used (Southam A. and Janowskin A, 1962; Sassi 
D, et al., 1964), the disease was already defined before this official classification. 
OHSS appeared to be a possible complication of the induction of ovulation by 
using gonadotropins in controlled ovarian hyperstimulation (COH) protocols. The 
presentation and severity of this syndrome has evolved over time in relation to 
such protocols, for example, the development of in vitro fertilization (IVF) 
techniques in the late 80s and early 90s led to more aggressive treatments in order 
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to obtain sufficient numbers of oocytes and embryos, consequently leading to a 
greater risk of OHSS (Golan A, et al., 1988; Aisaka K, et al, 1989; McClure N, et al, 
1992; Urman B, et al, 1992, MacDougall M, et al., 1993).  
Due to the importance of this syndrome many groups have studied its symptoms 
and pathophysiology, and have developed techniques that can prevent or reduce 
its incidence. Although there have been many different lines of investigation which 
have brought great advances in the understanding and prevention of OHSS, its 
pathophysiology, the intrinsic molecular mechanisms at the  origin of this 
syndrome, and knowledge of why these mechanisms function differentially in 
different patients remains unclear. 
 
1.2. DEFINITION 
OHSS is an iatrogenic complication of the luteal phase and/or early pregnancy 
(Kasum et al, 2010). It is an exaggerated response to COH, characterized by 
increased ovarian size, large internal cysts, and extravasation of intravascular fluid 
into the third space due to increased vascular permeability (VP) in response to 
administration of the exogenous gonadotropins (mainly human chorionic 
gonadotropin; hCG) used to induce ovulation (Gómez R, et al, 2010). While mild 
OHSS has almost no clinical relevance, severe OHSS is characterized by massive 
ovarian enlargement, ascites, pleural effusion, oliguria, hemoconcentration, edema 
in the third space, disturbed electrolyte balance, hydrothorax, and thrombotic 
events (Shenker and Weinstein, 1978; Navot D, et al., 1992; Schenker J. and Ezra 
Y, 1994; Serour G et al., 1998; Hock D, and Seifer D, 2000), which can endanger 
the life of the patient 
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1.3. SYMPTOMS 
OHSS predictive signs and symptoms, such as increased ovary size, can be 
observed even at the early stages of the ovarian stimulation cycle, although the 
total manifestation of the syndrome, expressed as an increase in VP and the 
output of protein-rich fluid from the intravascular space, occurs in the post-
ovulatory phase (or after oocyte recovery). The different manifestations which 
characterize OHSS are described below: 
1.3.1. VASCULAR COMPLICATIONS 
The mechanism responsible for the clinical manifestations of OHSS seems to be 
an increase in the VP, which causes fluid to shift into the intravascular space 
(Polishuk W, et al., 1969). Patients who suffer this clinical manifestation can suffer 
from several cardiovascular effects, which include low blood pressure, low blood 
volume, low central venous pressure, tachycardia, increased cardiac output, low 
peripheral resistance, hemoconcentration, and hypercoagulation (Cremisi H. and 
Mitch W, 1994). High hematocrit directly reflects a decrease in intravascular blood 
volume and an increase in viscosity which can both influence renal perfusion and 
thromboembolic events. Hypovolemia, associated with loss of fluid and proteins 
into the abdominal cavity, can induce oliguria and electrolyte imbalances. In some 
cases it may trigger clinical complications, such as decreased renal perfusion 
which occurs in approximately 1.4% of the severe forms of OHSS (Abramov Y, et 
al., 1999; Khalaf Y, et al, 2000).  
Patients with severe OHSS exhibit compensatory endogenous vasoconstrictor 
activity: an increase in cardiac output and blood volume as a result of the retention 
of sodium and water, although this is not sufficient to maintain homeostasis. This is 
the most severe form of OHSS since the reduced blood volume can cause 
peripheral arteriolar vasodilation (Balasch J, et al, 1998). In patients with moderate 
OHSS, the degree of arteriolar vasodilation is not as intense, and so homeostasis 
and blood pressure are normal and no edema or hemoconcentration is observed 
(Balasch J, et al., 1998). 
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1.3.2. CLINICAL SYMPTOMS 
The onset of clinical symptoms can be observed from the end of ovarian 
stimulation by a high ovarian response which implicates an increased ovary 
volume. The first symptoms, including nausea, vomiting, and abdominal pain, can 
appear 48 hours after hCG administration and these usually progress rapidly within 
the first few days after follicular aspiration, and become severe around 7-10 days 
after hCG administration. Some patients develop ascites on day 7 after hCG 
administration. Symptoms improve slowly with rapid diuresis within 48 hours of the 
onset of menstruation if pregnancy does not occur, but if there is a pregnancy, the 
symptoms become aggravated due to the secreted hCG. It is unusual to find 
serious cases of OHSS syndrome without pregnancy, however, when it does occur 
the duration is shorter.  
There are several clinical complications that can occur, as a consequence of 
OHSS which are described in the following. 
1.3.2.1. Obstetric complications 
- Ectopic pregnancy: This is relatively common in cycles with conception, 
perhaps due to ovarian enlargement (Ballesteros A, et al., 1999). 
- Obstetric morbidity: In complicated pregnancies which present severe OHSS, 
a higher rate of multiple pregnancies, spontaneous abortion, prematurity, low 
birth weight, preeclampsia, gestational diabetes, and placental abruption are 
observed in pregnancies generated by assisted reproduction but no 
associated with this syndrome (Mathur R. and Jenkins J, 2000a). 
Most of these complications can be explained by the higher incidence of multiple 
pregnancies. The abortion rate in pregnancies complicated with OHSS ranges from 
27-40%, which is higher than the abortion rate described in assisted-reproduction 
pregnancies not complicated by OHSS (18-22%; Chen C, et al., 1997; Schenker J. 
and Weinstein D, 1978). 
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1.3.2.2. Gynecological complications 
- Intraperitoneal hemorrhage, caused by the rupture of a corpus luteum. 
- Adnexal torsion: This may cause any combination of ovarian enlargement, 
abdominal pain, nausea, progressive leukocytosis, or anemia (Mashiach S, et 
al., 1990). 
- The persistence of large ovarian cysts. 
1.3.2.3. Ascites 
Accumulation of fluid in the abdominal cavity can lead to tense ascites with 
increased intra-abdominal pressure. This generates a decrease in venous blood 
return, resulting in hypovolemia and oliguria, and secondary respiratory distress 
with dyspnea. 
1.3.2.4. Thromboembolic events 
Thromboembolic events are most frequent when hemoconcentration is present, but 
they may also appear in its absence and/or in the presence of low levels of 
antithrombin III (Kaaja R, et al., 1989). These findings support the hypothesis that 
high levels of estradiol and progesterone play a role in the etiology of deep venous 
thrombosis associated with OHSS. 
1.3.2.5. Acute renal failure 
This complication is usually due to hypovolemia and a renal perfusion deficit 
(Balasch J, et al., 1990). Acute renal failure presents clinical manifestations such 
as oliguria, disturbed electrolyte balance, azotemia, and dilutional hyponatremia 
associated with antidiuretic hormone hypersecretion. 
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1.3.2.6. Liver disease 
Cholestatic or hepatocellular lesions have been associated with high estradiol (E2) 
levels and hepatic edema due to increased VP (Younis J, et al., 1988; Ryley N, et 
al., 1990). 
1.3.2.7. Pulmonary alterations 
- Pleural effusion by increasing VP. 
- Acute hydrothorax with severe pulmonary involvement (Padilla S, et al., 
1990). 
- Acute respiratory distress syndrome (ARDS): severe hypoxemia associated 
with this syndrome can lead to cardiac arrest (Zosmer A, et al., 1987). 
 
1.4. CLASSIFICATION 
OHSS was first classified in 1967 (Rabau E, et al., 1967) by combining both 
laboratory and clinical findings. Several years later, in 1978, Schenker J. and 
Weinstein D. reorganized and modified the classification into three main clinical 
categories (mild, moderate, and severe) and six grades according to the severity of 
the symptoms. In 1989, a new classification system with three categories and five 
grades was introduced (Golan A, et al., 1989), which included echographic 
evaluation of the ovary size and the presence of ascites as a criteria associated 
with OHSS. This classification method is the most widely accepted, because it 
incorporates both clinical signs and symptoms, and echographic and analytical 
findings. This was later modified by further dividing the severe form into two 
subgroups (severe and critical) which allow severe cases and those that endanger 
the life of the patient to be distinguished (Navot D, et al., 1992). The most recent 
classification with further modifications was introduced in 1999 (Rizk B. and 
Aboulghar M, 1999) and is described in the table below (Tabla.I) 
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1.5. EPIDEMIOLOGY 
It is not easy to estimate the incidence of OHSS as the mild grade cannot always 
be diagnosed, mainly because it is practically asymptomatic. Before the application 
of ART, Schenker J. and Weinstein D. estimated an incidence of 8-23% for the mild 
grades; 0.005-7% in moderate grades, and 0.008-10% in severe grades.  
This incidence increased when new ARTs were applied; 0.1-2% of severe OHSS 
(Busso C, et al, 2009), constituting the most serious complications described 
above, now present in patients undergoing ovulation induction treatments and 
ART. On average, two cases of severe OHSS are observed per 200 cycles of 
ovulation induction with the follicle stimulating hormone hCG, and one or two cases 
are hospitalized in the intensive care unit. The frequency and risk factor for OHSS 
is increased by 50% in cycles in which the pregnancy is already present, and is 
four times higher than that of non-pregnant cycles (Golan A, et al., 1989). The late 
manifestation of the syndrome is concomitant with pregnancy in 96.7% of cases, 
and a severe manifestation is also more likely to develop in these cases than in 
early-diagnosed OHSS (Papanikolaou E, et al., 2005).  
Severe OHSS currently occurs in approximately 1.4% of all cycles (Fiedler K and 
Ezcurra D, et al., 2012) and the risk of mortality is estimated to be 1 in 450,000 to 
500,000 cases. This low incidence appears to be due to improved monitoring of 
ovulation induction, better identification of risk factors, and probably also because 
of greater understanding and prevention of OHSS. 
 
1.6. RISK FACTORS 
Patients undergoing assisted reproduction treatments using IVF techniques should 
follow a personalized stimulation protocol which is adapted to each patient, after 
assessing the presence or absence of risk factors which can lead to OHSS. In 
1992, Navot D. et al. described some risk factors which have since been analyzed 
separately and confirmed by others (Delvigne A, et al., 1993). The risk factors 
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described by these studies allowed doctors to better predict OHSS and thus reduce 
its incidence. 
 Age: the risk of patients developing OHSS depends on their age. There is a 
higher incidence in younger women (under 35 years) who might be explained 
by the fact that a greater number of follicles are recruited in these patients 
(Gaona R, et al., 2010) and that they have a higher number of gonadotropin 
receptors.  
 Body mass index (BMI): There are conflicting results regarding the relationship 
about BMI in the development of OHSS (Lee T, et al., 2008; Delvigne A, et al, 
2002). Therefore, BMI does not appear to be a useful marker for increased risk 
of OHSS. 
 Number of follicles recruited: Several studies have demonstrated that 
recruitment of more than 35 follicles increases the risk factor (Navot D, et al., 
1988; Enskog A, et al, 1999), even if these include small or intermediate 
follicles, due to their ability to produce E2 and vasoactive molecules. 
 Estradiol levels: E2 concentrations higher than 4,000 pg/ml on the day of hCG 
administration are related with OHSS (Navot D, et al., 1992). High levels of E2 
alone are not good predictors of the syndrome (Alper M, et al., 2009; 
Humaindan P et al., 2010; Papanikolau E. G., 2010). Nevertheless, a 
combination of the number of follicles recruited and the E2 serum levels is a 
good predictor of OHSS, providing high sensitivity and specificity 
(Papanikolaou E, et al., 2006). 
 
 hCG administration: Administration of exogenous hCG to induce ovulation is 
associated with OHSS due to its role in stimulation by neovascularization and 
increasing VP (Brinsden P, et al., 1995). Use of hCG in the luteal phase after 
the IVF cycle instead of progesterone is also associated with OHSS (Navot D, 
et al., 1992). 
 Anti-Müllerian Hormone (AMH): AMH is expressed in the granulosa cells (GCs) 
of preantral and small antral follicles (Humaidan P, et al., 2010; Durlinger A, et 
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al, 2002) and measuring it gives a good estimation of ovarian reserve. Initial 
studies found that all the cycles that were cancelled due to a risk of OHSS 
were in patients whose AMH levels were greater than 7 ng/ml. This suggests 
that AMH is a predictor of ovarian response (La Marca A, et al., 2007; Gnoth C, 
et al., 2008), which can differentiate normal  responders (AMH levels of 1.26 
ng/ml) with a success rate of 98% (Hehenkamo W, et al., 2006). 
 Polycystic ovary syndrome (PCOS): women with PCOS have a higher 
incidence of developing OHSS after administration of exogenous 
gonadotropins than women who present other causes of anovulatory infertility. 
This is due to the high number of follicles recruited by these patients. Studies 
show that 14.7% of patients with OHSS are PCOS patients, thereby indicating 
that PCOS is an OHSS risk factor. 
The implication of this risk factor in the OHSS and the relationship between 
them has been studied in this thesis. For this reason, a special section to 
describe the PCO syndrome has been engaged. 
 
1.7. POLYCYSTIC OVARIAN SYNDROME (PCOS)  
PCOS was first described in 1935 and was characterized by the presence of 
Polycystic ovaries (PCOs), menstrual irregularities, and clinical/biochemical 
hyperandrogenism (Stein I. and Leventhal M. et al., 1935). Development of PCOS 
has been linked to hereditary and environmental factors including genetics, insulin 
resistance, obesity, and birth weight, and is associated with chronic 
oligoanovulation and a typical PCO morphology (Rotterdam ESHRE/ASRM-
Sponsored PCOS Consensus Workshop Group 2004).  
1.7.1. The clinical features of polycystic ovary syndrome 
The commons symptoms which characterize PCOS include:  
 Menstrual disorder: PCOS patients are mostly oligomenorrheic, which is 
defined as a menstrual interval of more than 35 days or amenorrhea (which is 
defined as the absence of menstrual bleeding for more than 90 days). Some 
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women with PCOS may have normal menstruation patterns but they may not 
ovulate (chronic anovulation).  
 Infertility: this symptom results from anovulation (lack of ovulation). Menstrual 
disorders are one of the main reasons why PCOS women have difficulty 
becoming pregnant. 
 Clinical hyperandrogenism: Hyperandrogenism is one of the most noticeable 
features of PCOS. This symptom is caused by increased ovarian and/or 
adrenal androgen production. The primary clinical indicator of 
hyperandrogenism is the presence of hirsutism (Rotterdam ESHRE/ASRM-
Sponsored PCOS Consensus Workshop Group 2004 
 Biochemical hyperandrogenism: Androstenedione and testosterone serum 
levels should also be used in PCOS diagnosis. However specific cut-off points 
for hyperandrogenism have not been identified.  
 Metabolic signs: PCOS is also associated with obesity, insulin resistance, 
diabetes, and hyperinsulinemia. 
 Polycystic ovaries: The first definition of polycystic ovary (PCO) morphology 
in 1935  considered PCOs as “usually being bilateral, enlarged, tense ovaries 
which were often distinctly globular in shape, in addition to the presence of 
multiple cysts, which are rarely larger than 15 mm” (Stein I. and Leventhal M. 
et al., 1935). With the introduction of gynecological transvaginal ultrasound in 
the 1970s, the morphological diagnosis of PCO started to be made using 
ultrasound instead of ocular inspection or histology. Thus, PCOs are identified 
by the presence of at least one ovary with a size greater than 10 cm
3
 or the 
presence of 12 or more follicles between 2-9 mm in diameter.  
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Figure 5: Illustration of the characteristic clinical features of PCOS in women of fertile age and the 
possible consequences. 
 
1.7. 2. Polycystic ovary syndrome definitions and phenotypes 
The most recent PCOS definitions used are the following: 
 National institutes of health criteria 
Since it was first identified in 1935, there was no formal tool for diagnosing PCOS 
until it was defined and described in an expert conference sponsored by the 
national institutes of health (NIH) in April 1990. Patients who presented ovulatory 
dysfunction (oligo- or anovulation) and hyperandrogenism, with the exclusion of 
known disorders, such as Cushing’s syndrome, hyperprolactinemia, non-classical 
congenital adrenal hyperplasia, and androgen-secreting tumors were diagnosed 
with PCOS (Table 2). 
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 Rotterdam criteria 
The Rotterdam criteria were established in 2003 and revised in 2004 (Rotterdam 
ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group 2004) by the 
European society for human reproduction and embryology (ESHRE) in 
collaboration with the American society for reproductive medicine (ASRM). Experts 
in Europe believed that PCO morphology should be considered as a diagnostic 
criterion. This definition required at least two of the three following criteria: oligo- or 
anovulation, clinical and biochemical signs of hyperandrogenism, and/or PCOs 
(Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group, 2004; 
Table 2). However, the Rotterdam 2003 criteria did not replace the NIH 1990 
criteria, because all women diagnosable by the NIH criteria also meet the 
Rotterdam definition (Table 2). 
 
 Androgen excess society criteria  
In 2006, the androgen excess society (AES) proposed that the criteria for the 
diagnosis of PCOS should be tightened (Azziz R, et al., 2006). They included a 
requirement for hyperandrogenism in combination with ovarian dysfunction. The 
diagnosis criteria were changed again to include excess androgen as a necessary 
component along with the exclusion of other etiologies.  
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Study Criteria 
NIH, 1990 To include all of the following: 
1) Oligoovoulation 
2) Hyperandrogenism and/or 
hyperandrogenemia 
3) Exclusion of related disorders 
ESHRE/ASRM 
(Rotterdam, 2003) 
To include two of the following, in addition to 
exclusion of related disorders: 
1) Oligo- or anovulation 
2) Clinical and/or biochemical signs of 
hyperandrogenism 
3) Polycystic ovaries 
AES, 2006 
 
To include hyperandrogenism in combination with: 
1) Oligo- or anovulation 
2) Polycystic ovaries 
 
Depending on the PCOS definition used, different phenotypes exist. The division 
into phenotypes is based on the characteristics: oligo-/amenorrhea, 
hyperandrogenism, and PCO. Currently, the NIH, Rotterdam and AES criteria 
remain the three main diagnostic tools for PCOS. In this thesis, PCOS is defined 
according to the Rotterdam criteria, which currently seem to be the most commonly 
used criteria (at least in Europe). 
1.7.3. Etiology and pathophysiology of polycystic ovary syndrome 
Although the cause of PCOS is currently unknown, multiple mechanisms have 
been discussed which involve interactions between heritable and environmental 
factors (Norman R, et al., 2007; Ehrmann D, 2005). These factors include genetics, 
insulin resistance, obesity, and birth weight (which is related to the adipose tissue 
hypothesis. 
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1.7.3.1. Genetics 
In spite of numerous studies on genes associated with the synthesis and 
metabolism of androgens and insulin, it is not known how PCOS is inherited. 
Recent studies provide support for a genetic component of PCOS with evidence of 
the disorder occurring among women in the same family (Govind A. et al., 1999; 
Carey A, et al., 1993; Lenarcik A, et al., 2011). Although it appears to be an 
autosomal dominant disease, there is not currently enough evidence to prove this 
theory. 
1.7.3.2. Insulin resistance 
Insulin resistance is a pathogenic characteristic feature of PCOS (Dunaif A, et al, 
1989), which occurs in 5-70% of the PCOS population. The molecular mechanism 
of insulin resistance involves defects in the insulin-receptor signaling pathway in 
both adipocytes and in skeletal muscle (Dunaif A, 1997). Insulin resistance causes 
compensatory hyperinsulinemia and may contribute to hyperandrogenism and 
gonadotropin aberrations. It is known that ovarian stimulation is exerted by a 
synergistic effect of insulin upon LH theca cell-stimulation (Diamanti-Kandarakis E, 
et al., 2008; Nestler J, et al., 1997).Hyperinsulinemia also stimulates androgen 
production, which starts and/or maintains a positive feedback loop in which 
hyperandrogenism leads to hypothalamus/pituitary abnormalities, ovarian 
dysfunction, insulin resistance, and obesity, which in turn stimulates further 
androgen production (Escobar-Morreale H. and San Millan J, 2007).  
 1.7.3.3. Obesity 
Obesity is another component of PCOS which may contribute to its pathogenesis. 
In PCOS women, excess weight is primarily in the abdominal region; when 
abdominal adipose tissue is broken down free fatty acid levels in the circulation rise 
leading to chronic hyperinsulinemia. As mentioned above, insulin resistance is a 
key feature in the development of PCOS, further helping to explain why obesity 
increases the symptoms of PCOS. 
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1.7.4. Reproductive implications of polycystic ovary syndrome 
Anovulation (oligo- or amenorrhea) and concordant infertility are frequently the first 
clinical manifestations of PCOS (Goverde M, et al., 2008). Approximately 70% of 
PCOS patients remain undiagnosed (Teede H, et al., 2011) therefore making it 
difficult to know what proportion of PCOS patients are infertile. In general, PCOS is 
associated with a lower chance of conceiving and higher miscarriage rates 
(Pasquali R, et al. 2006); this may be due to the severe features of PCOS, such as 
amenorrhea and grave hyperandrogenism, which are associated with enduring 
anovulation and worse treatment outcomes (Balen A, et al. 1995). Moreover, once 
pregnancy is established in PCOS women, they are at an increased risk of 
pregnancy complications such as gestational diabetes, pregnancy-induced 
hypertension, and preeclampsia (Boomsma C, et. al., 2006; Kjerulff L, et al., 2011).   
The first line of treatment for infertility associated with PCOS is weight reduction 
(Norman R, et al., 1998). The second option is conventional ovulation induction 
treatment, which is widely used in PCOS although it may lead to a higher risk of 
OHSS (Van Wely M, et al., 2003): 15% of PCOS women undergoing ovulation 
treatment suffer from severe OHSS, compared to 3% of control women (Swanton 
A, et al., 2009). Towards the end of the 1990s, in vitro maturation (IVM) was 
developed, mainly with the purpose of avoiding OHSS in PCOS women. Although 
thus far the IVM technique is not widely used because there is a higher 
cancellation rate of IVM cycles compared with IVF, the aspiration process is more 
difficult, and the success rate is lower than IVF (Suikkari A, 2008). 
 
1.8. PATHOPHYSIOLOGY OF HYPERSTIMULATION SYNDROME 
The pathophysiological mechanisms of OHSS remain unclear, nevertheless it is 
widely accepted that this pathology is caused by an exaggerated response to 
COH. This response is characterized by generalized capillary leakage and an 
acute shift of protein-rich fluid (mainly albumin) from the vascular space into the 
peritoneal pleural, and to a lesser extent into the pericardial cavities. This process 
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is triggered when ovaries increase their size due to follicular stimulation, and leads 
to the characteristic hemodynamic alterations of OHSS, such as ascites, 
hydrothorax, and generalized edema.  
This shift of protein-rich fluid is due to an increase in the VP after hCG 
stimulation.  The severity of this process depends on the degree of the ovarian 
follicular response to the ovulation induction agents (Schenker J, et al., 1999). 
Hence, the root cause of OHSS is the development of multiple follicles. In a 
spontaneous ovulatory cycle, there are very efficient negative feedback 
mechanisms which ensure the development of only one dominant follicle. This 
follicle is ovulated in response to luteinizing hormone (LH) in the middle of the 
cycle. In a gonadotropin-stimulated cycle, this endogenous self-regulation does not 
exist; to ensure successful therapy exogenous hCG is administered in order to 
activate and maintain several antral follicles at once. This allows multiple follicles 
(rather than only one) to start and finish development, thus increasing the risk of 
developing OHSS. 
1.8.1. Human chorionic gonadotropin 
hCG is used to stimulate the LH receptor in assisted reproductive cycles, in order 
to initiate the final phases of both follicular and oocyte development. The biological 
activity of hCG is approximately 6-7 times that of LH due to its long half-life and its 
affinity for the LH receptor (Soares S, et al., 2008). hCG is considered an essential 
factor in the development of OHSS, even though  this hormone does not have 
vasoactive properties, making it hard to believe that it is directly responsible for the 
development of OHSS (Gómez R, et al., 2002). If hCG were a vasoactive factor 
which acted directly on the ovaries, all women with OHSS would present elevated 
levels of hCG. However, despite high hCG levels being a risk factor, not all women 
with high hCG levels develop the syndrome. This data suggests that mechanisms 
other than hCG also trigger OHSS, most likely some mechanism which is triggered 
by hCG administration.  
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1.8.2. VASOACTIVE FACTORS 
Experiments carried out on animals have demonstrated a direct and positive 
correlation between increase in the ovary size, increased VP, the severity of 
ascites, and the gonadotropin dose (Schenker J. and Weinstein D, 1978; Gómez 
R, et al., 2003a), suggesting that the development of ascites is secondary and is 
related to the rise in VP, which is in turn related to the dose of hCG. Given that 
hCG does not have vasoactive properties per se we assumed that the increase in 
VP, which is the origin of and characterizes OHSS, must be mediated by 
vasoactive factors which are secreted at the systemic or ovarian level. This 
explains why most studies on OHSS aim to elucidate which substances or factors 
with vasoactive properties might mediate the action of hCG in increasing in VP. 
1.8.2.1. Estradiol 
Due to the high levels of sexual hormones that are associated with OHSS, the role 
of E2 in the pathophysiology of this disease has been particularly studied (Asch R, 
et al., 1991). At first it was considered that high E2 levels could be responsible for 
the increase in VP, although later this hypothesis was discarded when several 
studies proved that E2 is not necessary for the development of the OHSS. In fact, 
one patient had a deficiency in CYP17A1 enzyme activity but still developed OHSS 
during IVF treatment despite the low levels of E2 resulting from this deficiency 
(Pellicer A. et al., 1991). Moreover, high E2 levels only appear if hCG levels are 
high (Aboulghar M, et al., 2003). Additionally, recent work has shown that 
administration of gonadotropin-releasing hormone (GnRH) causes a reduction in 
E2 levels which is directly linked with a decrease in vascular endothelial growth 
factor (VEGF) levels, reducing the incidence and severity of OHSS (Gustofson R, 
et al., 2006; Tong X, et al., 2008; Cerrillo M, et al., 2009; Cerrillo M, et al., 2010). 
Hence E2 levels are now considered to be one of the best OHSS risk predictors: 
women at a high risk of developing OHSS present high levels of E2 (more than 
2500 pg/ml) or a fast increase in E2 serum levels (The Practice Committee of the 
American Society for Reproductive Medicine, 2008). 
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1.8.2.2. Renin-angiotensin system (RAS) 
The existence of a direct correlation between the renin activity in plasma and the 
severity of OHSS has been described (Navot D, et al., 1987). The renin-
angiotensin system has an important role in the pathophysiology of the ovary, 
especially in the transition from the preovulatory follicle to the corpus luteum, a 
highly vascularized structure. Theca cells from the ovarian follicles contain pro-
renin as an inactive form of the renin enzyme (Paulson R, et al., 1989), which is 
activated in mid-cycle and catalyzes the conversion of angiotensinogen to 
angiotensin I (AI; Balen A, et al., 2008). AI is converted into angiotensin II (AII) by 
the action of the angiotensin-converting enzyme (ACE), after which AII promotes 
angiogenesis, increases VP, and stimulates the release of prostaglandins 
(Delbaere A, et al., 1997) and aldosterone.  
Due to the important role of the renin-angiotensin system (RAS) in the induction of 
new vessel formation and in increasing VP (Navot D, et al., 1987), it might be 
responsible for the ovarian enlargement and accumulation of extracellular fluid 
which occurs during OHSS. High levels of renin, ACE, AI, and AII were observed in 
follicular fluid (FF) and plasma in OHSS patients (Sealey J, et al., 1986; Navot D, et 
al, 1987; Derkx F, et al., 1987). Furthermore, these patients also had high levels of 
AII and ascites, indicating activation of the RAS pathway in the OHSS ovaries 
(Delbaere A, et al., 1997). However, RAS cannot be responsible for ascites, but AII 
might act to mediate the formation of ascites via other vasoactive cytokines 
involved in the development of OHSS, such as VEGF (McClure N, et al., 1994, 
Revel A, et al., 1996). Administration of ACE inhibitors during ovarian stimulation 
with gonadotropins in a rabbit OHSS model reduced the incidence and severity of 
OHSS (Teruel M, et al., 2001). However, teratogenic effects have been associated 
with use of ACE inhibitors and so they cannot be used in women attempting to 
conceive. 
 
 
INTRODUCTION 
22 
 
1.8.2.3. Prostaglandins 
It was initially thought that prostaglandins (PGs) had a key role in the development 
of OHSS (Schenker J. and Polishuk W, 1976) because they can induce OHSS 
directly or indirectly by increasing AII production. However, using the PG inhibitor 
indomethacin in rabbits, it was observed that blocking PG synthesis did not block 
the formation of ascites and enlarged ovaries (Pride S, et al., 1984), making it 
unlikely that they play a role in inducing OHSS.  
1.8.2.4. Histamine 
Histamine was originally seen as a possible OHSS mediator because the use of 
histamine receptor 1 inhibitors in rabbits inhibits the formation of ascites (Gergly R, 
et al., 1976) but several studies refute this possibility (Erlik Y, et al., 1979; Zaidise I, 
et al., 1983) because the levels of histamine in OHSS rabbits compared to controls 
is not different. It is not currently thought to be involved in mediating OHSS.  
1.8.2.5. Endothelin 
Vasoactive substances secreted by the endothelium, such as nitric oxide (NO), or 
endothelin (Vane J, et al, 1990, Battistini B, et al., 1993) maintain and regulate 
blood pressure. Although different roles for endothelin in the pathophysiology of 
reproduction have been suggested, its role as a possible OHSS mediator should 
also be highlighted (Goldsman M, et al., 1995; Elchalal U. and Schenker J, et al, 
1997), because of its homeostatic effect on the endocrine system and circulation, 
and also its ability to interact with other endogenous vasoactive substances. There 
are studies which demonstrate that endothelin is found in FF and corpora lutea, 
and that its production is stimulated by hCG, (Masaki T, et al., 1993; Abae M. et al., 
1994), which suggests that OHSS patient ovaries may overproduce this hormone.  
1.8.2.6. Nitric oxide (NO) 
NO has dilating effects on blood vessels and is produced by endothelial cells, 
macrophages, and certain groups of neurons. It is synthesized by NO synthase 
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(Griffith O. and Stuehr D, 1995; Snyder S, 1995) from L-Arginine, producing NO 
and L-Citrulline, and requires the presence of both the NADPH (the reduced form 
of nicotinamide adenine dinucleotide phosphate; NADP
+
) cofactor and oxygen. In 
neurons this molecule works as a neurotransmitter, conducting physiological 
signals through lipophilic cell membranes. When it is produced by endothelial cells 
in blood vessels it acts as a paracrine regulator, and in other cell types it is involved 
in cytotoxic signal transduction (Ben-Shlomo I, et al., 1994). During follicular 
development, an increase in NO is correlated with increased estrogen, and 
furthermore, NO can be increased with GnRH, human menopausal gonadotropin 
(hMG), and hCG treatment (Rosselli M, et al., 1994). In the process of ovulation, 
NO mediates the action of interlukin-1-beta (IL-1β), which induces the LH 
production necessary for ovulation (Ben-Shlomo I, et al., 1994; Bonello N, et al., 
1996). The neovascular response, and many other angiogenic cellular 
mechanisms, require NO and are triggered by vasoactive agents through 
mechanisms autoparacrins (Ziche M, et al., 1994). It is also important to highlight 
its relationship with VEGF, which is considered to be the main trigger of this 
vasoactive agent in OHSS. 
1.8.2.7. Inhibins 
Inhibins are produced by the ovary and their main function is to regulate follicle 
stimulating hormone (FSH) production by the pituitary gland via endocrine 
mechanisms in order to regulate ovarian steroidogenesis by autocrine/paracrine 
mechanisms (Baird D. and Smith K, 1993). Inhibins are heterodimers composed of 
α and β subunits, which are linked by disulfide bridges. Inhibin-A consists of an α-
subunit and a type-A β subunit, while inhibin-B is composed of an α subunit and a 
type-B β subunit. Both inhibin-A and inhibin-B are expressed by theca and GCs in 
follicles (Yamoto M, et al., 1992; Burns W, et al., 1990; Erämaa M, et al, 1993). 
Inhibin-B increases during the early follicular phase while inhibin-A stays at low 
concentrations (Groome N, et al., 1996; Schipper I, et al., 1998). Subsequently, the 
concentration of inhibin-B decreases and inhibin-A increases to a peak four days 
after the LH peak (LH+4). During the luteal phase inhibin-B decreases while 
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inhibin-A reaches its maximum concentration. Therefore, inhibin-B can be regarded 
primarily as a follicular hormone with a role in inhibiting FSH secretion during this 
phase, while inhibin-A is mainly a LH. Both inhibin-A and inhibin-B appear to be 
associated with follicular selection and therefore could be used to predict and 
monitor OHSS (Enskog A, et al., 2000).  
Inhibin-A: Inhibin-A concentrations remain elevated after embryo transfer in OHSS 
patients but decrease  in healthy patients which leads us to believe that inhibin-A 
production is elevated  in OHSS ovaries (Enskog A, et al., 2000). 
Inhibin-B: Inhibin-B concentrations are higher in FF obtained from gonadotropin 
stimulated cycles than those obtained from natural cycles (Magoffin D. and 
Jakimuk A, 1997). Therefore, inhibin-B is produced in antral follicles and especially 
in the dominant follicle in the natural cycle (Croome et al., 1996). However, the 
higher inhibin-B concentration in severe OHSS patients cannot be explained by the 
higher number of mature follicles, because it does not significantly differ with 
respect to the control group (Enskog A, et al., 1999), although enhanced GC hCG-
sensitivity might explain this difference in OHSS patients (Humaidan P, et al., 
2010).  
Because there are no significant differences in inhibin-B levels at the beginning of 
OHSS between OHSS and control groups, it is unlikely that this hormone is 
responsible for the acute effects of the disease such as the formation of ascites. It 
has been suggested that the high concentrations of inhibin found before the onset 
of OHSS might prepare the follicles to produce large quantities of some factors 
which cause increased ovarian VP in response to hCG stimulation (Tollan A, et al., 
1990). 
1.8.2.8. Interleukins 
Several studies have shown a correlation between inflammatory mediators such as 
plasma cytokines (interleukins 2, 6, and 8) and OHSS (Aboulghar M, et al., 1999). 
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Interleukin-2: Interleukin-2 (IL-2) is a glycoprotein with a half-life of 3 to 22 minutes 
which is produced by T cells and is released into the circulation. The release of this 
interleukin causes multiple toxic effects including the accumulation of extracellular 
fluid leading to ascites and pulmonary edema (Oppenheim J, et al., 1991). Its role 
in OHSS pathogenesis is debatable; several studies have shown that IL-2 
concentrations in serum and peritoneal fluid are significantly higher in patients with 
OHSS (Aboulghar M, et al., 1999), and Orvieto et al. observed high levels of IL-2 in 
FF from OHSS patients versus control groups. Moreover, this group suggested that 
the concentration of IL-2 in FF can be used to predict OHSS, and that it may cause 
VP through systemic action because it passes directly into the peritoneal cavity 
(Orvieto et al, 1995). In contrast, another study found that IL-2 was undetectable in 
peritoneal fluid from severe OHSS patients (Revel A, et al., 1996). It is difficult to 
explain these conflicting results, although its short half-life may play a role. 
Although there is no evidence for a role for IL-2 in the pathogenesis of OHSS it is 
thought that it may be involved in the increase in VP. 
Interleukin-6: Interleukin-6 (IL-6) is produced by monocytes, endothelial cells, T 
cells, and fibroblasts. It is involved in angiogenic processes which occur during 
ovarian follicle development and is linked to increased VP (Motro B, et al., 1990), 
and so it is thought that it could be involved in the development of OHSS, although 
exactly how remains unclear. Large amounts of IL-6 have been observed in ascitic 
fluid and serum from OHSS patients compared to control groups (Friedlander M, et 
al., 1993; Andus T, et al., 1992), supporting the hypothesis that it could serve as an 
OHSS marker (Aboulghar M, et al., 1999). IL-6 expression and its 
immunolocalization in OHSS patients has been studied in depth by Loret de Mola’s 
group, who observed IL-6 immunostaining in corpus luteum and luteinized 
granulosa cells (LGCs; Loret de Mola J, et al., 1996a, b). The same group found 
that this cytokine is increased in OHSS and investigated whether its preovulatory 
concentration could predict OHSS. However they found that the preovulatory-state 
values during ovarian stimulation were similar between controls and OHSS patients 
(Loret de Mola J, et al., 1996a) indicating that IL-6 does not seem to be useful for 
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predicting the syndrome before hCG administration. In contrast Geva’s group 
observed that high concentrations of IL-6 in FF at the time of oocyte aspiration, 
could predict early development of OHSS in high responders (Geva E, et al., 
1997). Similarly, a study by Chen et al. confirmed that an increased IL-6 
concentration in FF at oocyte recovery can be an early OHSS marker in patients 
undergoing IVF; additionally, IL-6 serum values on the day of hCG administration in 
IVF can distinguish patients with a high risk of OHSS (Chen C et al., 2000). These 
contradictory results have not yet allowed a relationship between IL-6 and OHSS to 
be firmly established. 
Interleukin-8: This cytokine has neutrophil chemotactic activity and is an important 
angiogenic factor which has also been implicated as a possible OHSS marker. 
However, it is strongly correlated with E2 serum concentration and therefore it may 
not be directly involved in the development of OHSS (Chen C, et al., 2000). It is 
also known that interleukin-8 (IL-8) concentrations in peritoneal fluid in OHSS 
patients are significantly higher than in controls, but these differences are not 
reflected in serum levels (Revel A, et al., 1996). The importance of IL-8 in 
predicting OHSS has not yet been studied in depth, although a recent study has 
shown that the presence of IL-8 in the FF has an effect on the permeability of 
endothelial cells in culture, which may indicate a relationship between IL-8 and 
OHSS (Chen S, et al., 2010). 
1.8.2.9. Vascular endothelial growth factor (VEGF) 
Although the pathophysiology of OHSS remains to be elucidated, it is known that 
OHSS is caused by the presence of both pro- and anti-angiogenic factors in the 
FF. Due to its vasoactive properties, the pro-angiogenic cytokine VEGF is, very 
likely, the most important known mediator of OHSS (Pellicer A, et al., 1999; Garcia-
Velasco J, et al., 2003). High levels of VEGF have been observed in the FF of 
patients suffering from OHSS, and several studies have highlighted the role of 
ovarian VEGF in mediating the development of OHSS (Doldi N, et al, 1997; 
Itskovitz-Eldor J, et al, 1997). Many studies have also shown that the concentration 
of VEGF in ascites fluid, serum, and plasma from OHSS patients is increased 
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(McClure N, et al, 1994 and Agrawal R, 1999). VEGF mRNA expression in LGCs is 
time and dose-dependent to the hCG (Neulen J, et al, 1995), and its high ovarian 
expression during OHSS development coincides with maximum VP. This 
relationship makes sense in the context of work establishing the close relationship 
between VEGF and hCG (Neulen J, et al, 1998), especially because the main 
factor that triggers OHSS is the administration of hCG which in turn stimulates 
VEGF secretion by GCs (Neulen J, et al, 1998; Fiedler K. and Ezcurra D, 2012), 
Figure 1. In fact, there are studies that clearly show how the GCs isolated from 
patients who later developed OHSS secrete larger amounts of VEGF in response 
to hCG than those collected from patients who did not develop OHSS after 
receiving hCG (Wang T, et al, 2002).  
 
 
Figure 1. The pathogenesis of OHSS. A) hCG stimulates granulose-lutein cells, which increase their 
VEGF-mRNA production. The VEGF produced and released by granulose-lutein cells binds to VEGFR-
2 on endothelial cell membranes and triggers an increase in VP.   
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There are two VEGF receptors produced by the endothelial cells (VEGFR-1 and 
VEGFR-2), and one of them exists in a soluble form in serum (sVEGFR-1), acting 
as a negative VEGF modulator. Excess VEGF increases the risk of OHSS, while 
excess sVEGFR-1 (and other anti-angiogenic factors) decreases the ovarian 
response and the risk of OHSS, although this is also accompanied by a decrease 
in the pregnancy rate (Pellicer A, et al, 1999). Total concentrations of serum VEGF 
have no value in OHSS risk assessment because of the natural variation in VEGF 
receptor-binding (Garcia-Velasco J, et al., 2003).  
 
1.9. OVARIAN HYPERSTIMULATION SYNDROME PREVENTION 
STRATEGIES 
It is not possible to completely prevent the occurrence of OHSS, but by identifying 
risk factors early on, and personalizing the ovarian stimulation protocol (La Marca 
A, et al, 2010) its incidence can be reduced. The COH protocol used should try to 
reduce the cycle cancellation rate and iatrogenic complications, including OHSS: a 
key factor in improving ART results (Nardo L, et al., 2009). 
 
Before starting COH, patients with a high risk of OHSS can be identified based on 
their risk profile or biomarkers, and their stimulation protocol can be adapted to 
their needs via the COH. If COH is not applied correctly, patients are more likely to 
experience OHSS. To minimize the risk of severe OHSS complications during 
COH, secondary preventive measures are usually applied; several preventive 
protocols have been proposed to reduce or minimize these risks and are described 
in the following sections. 
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1.9.1. PRIMARY PREVENTION STRATEGIES 
The different strategies known to reduce the risk of OHSS may be divided into two 
main types, primary prevention strategies and secondary prevention strategies. In 
primary prevention, the stimulation protocol is customized based on an initial 
assessment of the risk of developing OHSS, considering the different cases as low, 
normal, or high responders. Each of these is subjected to a different stimulation 
protocol in order to recruit a larger or smaller oocyte cohort depending on the type 
of responder they are. 
1.9.1.1. Gonadotropin-releasing hormone (GnRH) antagonist protocol 
In the 80s, GnRH agonists (GnRHas) were widely used for COH, which resulted in 
an increased incidence of OHSS (Humaidan P, et al., 2010). One possible 
explanation could be that pre-treatment to block endogenous gonadotropins 
requires an increased exogenous dose of FSH in order to promote ovarian 
stimulation. According to this hypothesis, unlike pretreatment with analoge agonits, 
GnRH antagonists (GnRHant) would quickly block the GnRH receptors therefore 
they would not need to be administered until just before the endogenous LH 
increase, typically at a follicle size of 12-14 mm. As follicle selection occurs at the 
beginning of the cycle, a small number of medium-sized follicles are produced. The 
lack of suppression of endogenous FSH during the early follicular phase means 
that a low dose of exogenous FSH is required for ovarian stimulation with GnRH 
antagonists (European Orgalutran Study Group, 2000; North American Ganirelix 
Study Group, 2001). Following on from this hypothesis, cycles in which antagonists 
are used would result in a lower incidence of OHSS compared with cycles in which 
agonists are used. This first emerged as a technique in 1988 (Itskovitz J, et al, 
1988), and since then a large number of studies have investigated the safety and 
efficacy of the use of GnRH antagonists in COH. 
Recent studies such as the Cochrane review (Al-Inany H, et al., 2006) have shown 
that the incidence of severe OHSS is significantly lower when using a protocol with 
agonists than when using antagonists (relative risk [RR] 0.61, confidence interval 
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[CI]: 95% (0.42 to 0.89), probability [p] = 0.01), and secondary prevention methods 
such as coasting and cycle cancellation were administered more frequently in 
patients where agonist protocols were used (RR: 0.44, CI: 95% (0.21 to 0.93), p = 
0.03 [49]). Moreover, a second meta-analysis (Kolibianakis E, 2006) observed that 
the incidence of OHSS was significantly lower in antagonist cycles than in agonist 
cycles (RR: 0.46, CI: 95% (0.26 to 0.82), p = 0.01). Apart from reducing the risk of 
OHSS, E2 levels immediately reduced after the administration of GnRH 
antagonists, which was associated with a decrease in VEGF secretion, and 
therefore also of VP (Gustofson R, et al, 2006, Tong X, et al, 2008; Vrtačnik-Bokal 
et al, 2009; Giles J, et al, 2009). 
However, despite these advantages, results from comparative studies have 
questioned the efficacy of GnRH antagonists with respect to results obtained from 
ART; for example, Humaidan et al. showed that the number of oocytes retrieved, 
fertilization rate, and embryo quality were similar in patients receiving GnRH versus 
those who received hCG (Humaidan P, et al, 2011), but there was a low pregnancy 
rate. The review by Cochrane concludes that, although shorter GnRH antagonist 
protocols significantly reduce the incidence of OHSS, they also lower the 
pregnancy and live birth rates compared to long standard protocols (Al-Inany H, et 
al, 2007). In contrast, other studies have found significant differences between both 
protocols when comparing live birth rates (Kolibianakis E, et al, 2006). Therefore 
based on current data, GnRH antagonists should be considered for use both in 
normal patients and high responders. 
1.9.1.2. Luteal-phase support with progesterone 
Higher steroid levels (estradiol and progesterone) present in the luteal phase after 
COH cause a impairment in this phase due to the negative feedback from the 
pituitary gland (Tavaniotou A, et al. 2001 and 2006), resulting in low levels of 
endogenous LH, which causes a reduction in implantation and pregnancy rates 
and an increase in the loss early pregnancies (Pritts E, et al., 2002). The use of 
hCG in luteal-phase support significantly counteracts these problems but is also 
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associated with an increased risk of OHSS and so it should be avoided when 
estradiol levels exceed 2700 pg/ml and when there are more than ten follicles 
(Fatemi H, et al, 2007). The use of progesterone (P4) seems to reduce this risk by 
half, and in addition improves pregnancy rates. Further evidence for the efficacy 
and safety of P4 comes from a prospective, multicenter, and randomized study of 
1,211 IVF patients (Doody K, et al., 2008) who received P4 as a luteal-phase 
support; these patients had higher birth rates (35%-38%) and a lower incidence of 
OHSS. 
1.9.1.3. In vitro oocyte maturation 
An alternative technique to prevent OHSS could be in vitro maturation of immature 
oocytes collected during follicular puncture. Using this technique, the oocytes 
mature in a defined culture medium over 24-48 hours, after which they are fertilized 
in vitro and the embryo can subsequently be transferred. In a study of 56 patients 
with a high risk of OHSS occurrence during COH, hCG was given when the 
dominant follicle reached a diameter of 12-14 mm; 66% of the oocytes matured, 
resulting in a 46% rate of clinical pregnancy following fresh embryo transfer, and no 
cases of severe OHSS (Lim K, et al, 2005). In other clinical trials done on women 
with PCOS where oocyte maturation was used, the pregnancy rates per embryo 
transferred were adequate (20-54%) and implantation rates were acceptable (5.5-
34.5%; Suikkari A, 2008). However, it should be highlighted that in vitro oocyte 
maturation is still an experimental procedure and that it is not yet considered an 
alternative fertility treatment. This is largely due to the technical difficulties in 
obtaining immature oocytes from unstimulated ovaries and cultivating them, 
because of the live birth rate is below that of conventional treatments, and as a 
result of a higher incidence of meiotic and chromosomal abnormalities when 
immature human oocytes are used (Lanzendorf S, 2006). 
1.9.1.4. Insulin-sensitizing agents 
Insulin resistance with compensatory hyperinsulinemia is thought to play a 
pathophysiological role in the ovarian dysfunction (Adashi E, et al., 1985; Barbieri 
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R, et al., 1986) and in hyperandrogenism (Dunaif A, et al., 1989; Nestler J, et al., 
1991; Humaidan P, et al., 2010) associated with PCOS. It is known that insulin 
stimulates VEGF protein expression and secretion (Prakash A, et al., 2009), and 
that this stimulation is significantly higher in women with polycystic ovaries (PCOs) 
(Stanek M, et al., 2007). These insulin-sensitizing agents may reduce the incidence 
of OHSS by improving insulin sensitivity and reducing the hyperinsulinemia 
produced by these agents, thus, this strategy reduces both the symptoms of PCOS 
and the risk of OHSS. This could be explained by the fact that the GCs from 
women with PCOS are more sensitive to insulin and therefore, at least in vitro, they 
secrete more VEGF (Stanek M, et al., 2007) which normalizes hyperinsulinemia 
and could induce a decrease in GC VEGF secretion. Agents used for this purpose 
include the insulin sensitizer thiazolidinedione, although this is associated with 
increased cardiac morbidity and therefore may be contraindicative for use in 
healthy PCOS women (Dunaif A, et al., 2008). However, metfromin is an 
inexpensive, effective, and safe alternative which sensitizes cells to insulin, and 
which has been reported to reduce the risk of OHSS in women with PCOS 
(Costello M, et al., 2006). 
1.9.2. SECONDARY PREVENTION STRATEGIES 
Secondary methods of preventing OHSS are practiced when there is a risk factor 
resulting from excessive ovarian response after ART, and include the withdrawal, 
reduction, delay, or modification of elements of the stimulation protocol in order to 
prevent OHSS in these patients.  
1.9.2.1. Coasting 
Coasting, in order to prevent the OHSS, was first described in 1995 by Sher et al., 
and is a strategy in which hCG administration is postponed in women who respond 
to ovarian stimulation with high E2 plasma levels until those levels are considered 
to be safe. It is an alternative to cycle cancellation in situations where the serum E2 
levels are higher than 3000 pg/ml and there are more than 20 follicles. Follicular 
size is correlated with the FSH threshold and therefore, large follicles (which are 
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more resistant to apoptosis and atresia) continue to grow when the FSH levels 
decrease, while the apoptosis rate of the smaller follicles (under 14 mm) increases. 
Coasting leads to selective regression of immature follicles, reducing the number of 
GCs available for luteinization, and resulting in a decrease in the vasoactive 
substances involved in the pathogenesis of OHSS, such as VEGF. Coasting has 
been used to reduce the incidence of OHSS in high-risk patients without affecting 
the cycle, as shown in several studies (Alper M, et al., 2009; Levinsohn-Tavor O, et 
al., 2003; García-Velasco J.A et al., 2004; Youssef M, et al., 2010).  
Although it has been widely used, and retrospective studies have shown that 
coasting is effective, there is not currently sufficient evidence to recommend its use 
in routine practice. A careful review (Levinsohn-Tavor O, et al., 2003) concluded 
that coasting should be used in patients who present serum E2 levels higher than 
3000 pg/ml and a follicle size between 15-18 mm, until E2 levels drop to safe levels 
below 3000 pg/ml. If it takes more than three days for these levels to drop it is 
advised that the embryos should be frozen because data shows that thereafter the 
pregnancy rate decreases within that cycle.  
1.9.2.2. Reduced human chorionic gonadotropin (hCG) dose 
HCG is used in ovarian stimulation treatments to trigger ovulation or to provoke 
oocyte maturation in IVF cycles. The most commonly used dose is 10,000 IU but it 
is known that these hCG doses may cause OHSS in certain patients. Decreasing 
the standard doses used to trigger oocyte maturation in these patients can prevent 
OHSS; 5,000 IU have been successfully used to trigger ovulation without impairing 
clinical outcome (Schmidt D, et al., 2004; Kolibianakis E, et al., 2007; Humaidan P, 
et al., 2010). Promising results have also been reported by Cornell using a low-
dose protocol, who determined the hCG dosage according to serum E2 levels on 
the day of hCG administration. The levels of hCG administered are between 5,000 
and 3,000 IU in women with E2 levels between 2,000 and 3,000 pg/ml. Women 
with levels of E2 higher than 3,000 pg/ml undergo coasting until E2 falls below 
3,000 pg/ml (Humaidan P, et al., 2010). 
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A retrospective study of 250 cycles, which compared a dose of 5,000 IU versus 
3,300 IU, observed that the latter dose is as equally effective at triggering oocyte 
maturation in ART as the former, and do not adversely affect the results of the 
cycle (Schmidt D, et al., 2004). However, other studies have shown that a dose of 
2,000 IU is not sufficient to trigger oocyte maturation (Kashyap S, et al., 2010). 
Currently the benefits of low hCG doses for OHSS prevention are unclear, because 
data are scarce and the studies that have been conducted have small sample 
sizes and do not have a statistical power high enough to detect a significant 
difference in the rate of OHSS. 
1.9.2.3. Cryopreservation of all embryos and oocytes 
Cryopreservation is considered a traditional strategy to prevent OHSS when using 
COH techniques. This strategy consists of stimulating the normal cycle without 
transferring the embryos, instead cryopreserving them for transfer later when the 
patient’s hormone levels are lower. Thus, although the early phases of OHSS can 
occur (Aboulghar M, et al., 2003; Wada I, et al., 1992; Queenan J, et al., 1997; 
D’Angelo A. and Amso N, 2002) later stages are prevented because the high levels 
of hCG associated with pregnancy are avoided (Wada I, et al., 1992; Amso N, et 
al., 1990; Salat-Baroux J, et al., 1990). Cryopreservation appears to reduce, but 
not eliminate, OHSS without adversely affecting pregnancy rates (Sills E, et al., 
2008; Ferraretti A, et al., 1999), and in addition it has a higher pregnancy rate than 
coasting (Gera P, et al., 2010). However, this procedure does present risks, as 
shown by a retrospective study in which the maternal death rate due to OHSS was 
elevated in women whose embryos had been frozen due to previously observed 
OHSS symptoms (Braat D, et al., 2010). 
Recently, interest in cryopreservation has increased due to the introduction of 
vitrification: an efficient cryopreservation method which improves survival after 
thawing. Because vitrification very quickly converts liquid to solid without forming 
ice crystals the damage inflicted upon embryos by freezing with traditional 
cryopreservation techniques is significantly reduced. Several studies have shown 
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that in ART vitrification is associated with better results than slow cooling (Busso C, 
et al, 2010). Embryo vitrification has proved very successful for preventing OHSS 
in women at a high risk of the syndrome (Selman H, et al., 2009). Moreover, one 
study showed a pregnancy rate of 36.9% when using vitrification, a rate three times 
higher than using traditional cryopreservation (Al-Hasani S, et al., 2007). 
1.9.2.4. Cycle cancellation 
hCG administration is one of the major OHSS risk factors. Cancelling the cycle is a 
strategy which is considered in patients whose scans show significant follicular 
development and/or have serum E2 levels that are too high. Although this 
prevention technique is the most effective, it is costly and psychologically 
demanding on patients. Therefore, this technique is generally reserved for patients 
at the highest risk of OHSS. 
1.9.2.5. Alternative agents for triggering ovulation 
hCG has been successfully used to trigger ovulation for over 60 years, however, 
the relatively long half-life of hCG in serum results in prolonged luteotropic effects 
(Damewood M, et al., 1989), the development of multiple corpus luteum, and 
increased levels of E2 and P4 in the serum throughout the luteal phase (Itskovitz J, 
et al., 1991), which increases the risk of OHSS (Humaidan P, et al., 2010). 
Therefore alternative agents for triggering final oocyte maturation and ovulation 
have been investigated. 
Recombinant luteinizing hormone: Studies using recombinant LH (rLH) as a 
possible alternative to hCG for triggering ovulation showed that moderate OHSS 
was observed in 12% of patients who received two doses of recombinant LH 
compared to 12.4% of patients who received hCG, but did not observe moderate or 
severe OHSS in patients who received a single 30,000 IU dose of recombinant LH 
(The European Recombinant LH study Group, 2001). These results showed that a 
single dose of rLH (5,000 IU of hCG) is effective at inducing follicular maturation 
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and early luteinization, although despite its clear effectiveness at reducing OHSS 
its high cost makes it an unfeasible alternative.  
Gonadotropin-releasing hormone: The GnRHas do not physiologically stimulate 
an endogenous LH peak when used to induce ovulation (Hoff J, et al., 1983; 
Itskovitz J, et al., 1991). Whereas hCG is detectable in serum for up to six days 
after intramuscular injection of (5,000 IU), a single injection of GnRHa results in a 
combination of FSH and LH peaks which lasts for 34 hours (Gonen et al., 1990). 
Therefore, the short duration of LH activity after GnRHa administration, as 
compared to hCG, may reduce ovarian stimulation in the luteal phase (Segal S. 
and Casper R, 1992). 
Several studies have described a GnRHa ‘flare up’ effect in which the pituitary 
gland induces endogenous LH and FSH peaks (Bentick B, et al., 1988; Emperaire 
J.  and Ruffie A, 1991). One or two GnRHa doses were administered to six 
patients, causing an increase in LH/FSH, and resulting in a moderate response in 
most patients, and an exaggerated response in eight subjects (Itskovitz J, et al., 
1991). The levels of E2 and P4 were lower in patients who were administered 
GnRHas than in patients injected with hCG, and there were no signs of OHSS. 
These findings have since been backed up by similar results obtained by others 
(Imoedemhe D, et al., 1991.; Van der Meer S, 1993; Balasch J, et al., 1994; Shalev 
E, et al., 1994). In one study in which 179 women received 5,000 IU of either hCG 
or GnRHa to trigger follicle maturation, E2 concentrations were comparable in both 
groups and there were no cases of OHSS (Segal S. and Casper R, 1992). 
1.9.2.6. Albumin and hydroxyethyl starch (HES) administration 
Albumin is a protein present in plasma which can bind to the vasoactive agents 
responsible for the development of OHSS thus facilitating their removal from 
circulation. It has been proposed that intravenous administration of albumin during 
oocyte recovery could be used as a preventive measure in women at a high risk of 
the syndrome (Asch R, et al., 1993). The mechanism of albumin action is unknown 
but it is thought to block the vasoactive substances implicated in OHSS 
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pathogenesis and additionally, to increase the intravascular osmotic pressure, 
which prevents water loss from the intravascular compartment.  
There are multiple studies with contradictory results about albumin use, but a 
careful meta-analysis (Aboulghar M, et al., 2002) reported that albumin use during 
follicular aspiration decreased the incidence of severe OHSS in high-risk women. 
However, the optimal dose of albumin and timing for its use are unclear, and it is 
unknown how it effects embryo implantation. There are some studies which do not 
agree with the use of intravenous albumin: a controlled study with 988 patients 
clearly concluded that the use of albumin at the time of oocyte recovery did not 
prevent OHSS (Bellver J, et al., 2003). The use of albumin also has side effects, 
such as fever, nausea, vomiting, and possible anaphylactic reactions. Furthermore, 
as it is a human biological product there is also the potential risk of the 
transmission of viruses and prions. 
Hydroxyethyl starch (HES), a colloidal plasma substitute, has been used as an 
alternative to albumin as it causes an increase in intravascular volume and osmotic 
pressure. Its molecular weight is greater than that of albumin, and it has a half-life 
of about 10 hours. There are several studies which have published that HES is as 
effective as human albumin in preventing OHSS (Gokmen O, et al., 2001; Youssef 
M, et al., 2011) and moreover, it is free of the potential risks of albumin. Hence this 
method may be safer, cheaper, and more effective alternative to the use of albumin 
(Konig E, et al., 1998).   
1.9.2.7. Dopaminergic agonist administration 
Ovarian stimulation in PCOS patients leads a high risk of developing severe 
OHSS: prevention of the syndrome in these patients is difficult because there is a 
narrow margin between the dose required to produce a reasonable stimulation and 
the dose which induces OHSS. There is evidence that the release of LH has a 
dopaminergic component, so that pre-treatment with dopamine agonists, such as 
Cabergoline (Cb2), before inducing ovulation reduces the ovarian response to 
FSH, meaning that dopamine agonists could be used to prevent OHSS in PCOS 
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patients. Several studies have shown that if dopamine agonists, such as Cb2 and 
quinagolide, are given on the same day as hCG administration they may be able to 
reduce the incidence of OHSS by inhibiting VEGFR-2 phosphorylation in response 
to hCG (Gómez R, et al., 2010; Youssef M, et al., 2010), suggesting that Cb2 has a 
role in the secondary prevention of OHSS after ovarian stimulation. Two 
randomized trials have shown that Cb2 (0.5 mg/d) is more effective than 
intravenous albumin administration in preventing OHSS (Tehraninejad E, et al., 
2010; Carizza C, et al., 2008). Recent studies have also demonstrated that Cb2 
appears to reduce, but not eliminate, moderate OHSS and does not seem to affect 
the outcome of ART. Paradoxycally, dopamine agonists cannot prevent late OHSS 
(Gómez R, et al., 2010). Further study is still needed to confirm the efficacy and 
safety of Cb2 in primary and secondary prevention of OHSS during ovarian 
induction. 
1.9.3. UNRECOMMENDED STRATEGIES 
Follicular aspiration: The aspiration of GCs from an ovary, leading to intraovarian 
bleeding and limiting the production of OHSS mediators, allows the contralateral 
development of the other ovary. This strategy is not recommended because 
removal of the follicular aspirate is not easy, is costly, provokes patient discomfort, 
and is an invasive procedure which requires anesthesia.  
Aromatase inhibitors: Aromatase is involved in estrogen production (Santen R, et 
al, 2003) and it has been suggested that using inhibitors of this enzyme could help 
to reduce excessive estradiol synthesis during ovarian stimulation and 
consequently reduce the risk of OHSS. Although the anti-estrogenic effects of 
these agents seems promising in preventing or reducing the risk of OHSS, there 
are not many studies which evaluate the impact of aromatase inhibitors on OHSS 
in women with the anovulatory infertility associated with PCOS, and so they cannot 
yet be recommended for clinical use (Humaidan P, et al., 2010). 
 
 
 
                                                                                                INTRODUCTION  
   
39 
 
1.10. THE VASCULAR ENDOTHELIAL GROWTH FACTOR / RECEPTOR 
-2 SYSTEM 
1.10.1.  Vascular Endothelial Growth Factor (VEGF) 
Due to the important role of VEGF in OHSS, VEGF system must be described in 
detail. This growth factor was first described in the 80s as vascular permeability 
factor (Senger D, et al., 1983) and was later renamed vascular endothelial growth 
factor. VEGF plays an important role in regulating blood and lymph vesicle 
formation and in the maintenance of homeostasis. It is produced by endothelial, 
hematopoietic, and stromal cells in response to hypoxia and/or stimulation by other 
growth factors, such as interleukins or platelet growth factor. Specifically, VEGF 
interacts with hematopoietic cells, endothelial precursor cells, and differentiated 
mature endothelial cells. It is a heparin-binding homodimeric glycoprotein of 
approximately 40 kDa, which belongs to the PDGF (platelet-derived growth factor) 
family of growth factors. In mammals, the VEGF family consists in VEGF-A and its 
homologues VEGF-B, VEGF-C, VEGF-D, VEGF-E, and placental growth factor 
(PIGF). VEGF-A is the main member involved in angiogenic processes, while 
VEGF-B, VEGF-C, and VEGF-D are mainly involved in lymphangiogenesis. 
Recently, VEGF-C has been shown to be an important inducer of neurogenesis, 
without exerting angiogenic effects.  
The human VEGF-A gene is located on chromosome 6 (ep12; Wei et al., 1996) 
and is composed of 8 exons (Figure 2; Harper S. and Bate D, 2008); alternative 
splicing of exons 6 and 7 generates six molecular variants which have a different 
number of amino acids. In humans, these variants correspond to: VEGF121, 
VEGF145, VEGF165, VEGF183, VEGF189, and VEGF206 (Tischer E, et al., 1991: Houck 
K, et al., 1991), of which the most common and well-studied isoforms are VEGF121, 
VEGF165, and VEGF189. 
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Figure 2. Schematic representation of the different isoforms of human VEGF-A. a) Gene structure 
of human VEGF. b) Alternative splicing of exons 6, 7 and 8 generates six isoforms. Inclusion or 
exclusion of exons 6 and 7 enhances the ability of each isoform to bind and activate the VEGF 
receptors (VEGFRs).  
 
VEGF isoforms share the same N-terminal amino acid sequence, which contains 
the binding sites for VEGFR-1 and VEGFR-2 (contained by exons 3 and 4 
respectively), but may or may not contain the sequences encoded by exons 6 and 
7 in the C-terminus, due to the alternative splicing. This C-terminal region encodes 
two heparin-binding domains (HBDs), each of which confers the ability to bind to 
cell surfaces and extracellular matrix, thus determining the localization of the 
VEGF-A isoforms in the extracellular space. The VEGF-A145, VEGF-A189, and 
VEGF-A206 isoforms all contain two HBDs encoded by exon 6 and exon 7, and are 
therefore strongly sequestered in the extracellular matrix and on cell surfaces 
(Houck K, et al., 1992; Park et al., 1992), but are not secreted into the cytoplasm. 
Theses isoforms are detected in most tissues that express VEGF, except for 
VEGF-A206, which is only detected in human fetal liver (Houck K, et al., 1991). 
However, the binding efficiency of the VEGF-A isotype varies with the presence of 
HBDs; for example VEGF-A165, the predominant molecular form, only has one HBD 
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encoded by exon 7, meaning it has a reduced binding affinity and so while a 
significant proportion remains bound to the extracellular matrix, the other part is 
soluble (Houck K, et al., 1992). VEGF-A121 lacks the HBD and so it freely diffuses 
when it is secreted because does not bind to cell surfaces or extracellular matrix; it 
has been suggested that this isoform might form foci upon tissue injury, and may 
be required to form the new vessels required to repair tissues (Watkins R, et al., 
1999). 
1.10.2.  The role of vascular endothelial growth factor and its receptors in 
angiogenesis and vascular permeability 
The biological functions of VEGF polypeptides are mediated when they bind to 
type II receptor tyrosine kinases (RTKs), VEGFR-1 (Flt-1), VEGFR-2 (KDR/Flk-1), 
or VEGFR-3 (Flt-4) (Ferrara N, 2004; Shibuya M, et al., 1990; Terman B, et al., 
1991; Pajusola K, et al., 1992; Mattherws W, et al., 1991). These latter three 
consist of an extracellular domain comprising seven immunoglobulin (Ig)-like 
domains, a transmembrane domain, followed by a kinase domain divided into two 
parts by the insertion of a non-catalytic 100-amino acid residue sequence, and a C-
terminal tail (Cross M. and Claesson-Welsh L, 2001). These receptors are 
expressed on the cell surface of many cells, including hematopoietic cells (Kabrun 
N, et al., 1997), macrophages, endothelial cells (Ferrara N. and Savis-Smyth T, 
1997), some malignant cells (Bellamy W, 2002), and vascular smooth muscle cells 
(Ishida A, et al., 2001). VEGFs show distinct patterns of receptor specificity as 
indicated in Figure 3. The major signaling receptor for VEGF, mediating most of is 
biological activities in endothelial cells, is VEGFR-2, which seems to be more 
involved in the process of angiogenesis, vasculogenesis, and VP (Shalaby F, et al, 
1995; Verheul H, et al., 2000). 
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Figure 3. Schematic representation of VEGF ligands and their receptors. VEGF ligands are 
recognized by VEGFR receptors and carry out specific functions related to vascularization, such as 
angiogenesis and lymphangiogenesis. Placental growth factor (PIGF) can be recognized by VEGFR-1 
and carries out a similar function in angiogenesis.  
 
 
Angiogenesis is considered to be the formation of new blood vessels from pre-
existing endothelium (Folkman J. and Klagsbrun M, 1987). It is required for both 
the development and differentiation of the endothelium, such as in the repair 
damaged organs (Schwartz S, et al., 1990; Klagsbrun M. and D’Amore P, 1991). 
Several angiogenic regulators have been identified but the most important 
regulator is VEGF, which has potent angiogenic activity in both in vitro and in vivo 
studies (Zimmermann R, et al., 2001; Bates D, et al., 1996; Ferrara N, et al., 1992 
and 1997). VEGF facilitates angiogenesis in in vitro models, stimulating the 
formation of capillary-like structures and invasion of endothelial cells (Pepper M, et 
al., 1992). In vivo models have also demonstrated that VEGF has a strong 
angiogenic response (Folkman J. and Klagsbrun M, 1987: Klagsbrun and D’Amore, 
1991; Folkman J. and Davis-Smith T, 1992) and is a potent mediator of VP (Keck 
P, et al, 1989). 
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VEGF regulates vasculogenesis and angiogenesis during embryonic development 
(Millauer B, et al., 1993) and in adult tissues which require cyclic angiogenesis 
such as endometrium (Charnock-Jones S, et al., 1993; Torry D, et al., 1996) and in 
corpus luteum formation in women of reproductive age (Ravindranath N, et al., 
1992). This growth factor is also involved in diseases that are characterized by 
deregulated angiogenesis, and is elevated in the peritoneal fluid of women with 
endometriosis (McLaren J, et al., 1996). In vitro studies in which VEGF was 
activated in endothelial cells showed that this growth factor is able to induce 
changes in morphology (Senger D, et al., 1993), division, proliferation (Connolly D, 
et al., 1989; Whelan I. and Vlahos N, 2000), cell migration (Ferrara N, et al., 1992), 
increases in VP (Feng D, et al., 1996), angiogenesis (Leung D, et al., 1989; Ferrara 
N. and Davis-Smith T, 1997; Whelan I. and Vlahos N, 2000), and to promote the 
accumulation of cytoplasmic calcium (Brock T, et al, 1991). 
VEGF expression is regulated by several factors: hypoxia, cytokines, NO, and 
hormones. Hypoxia is a condition in which tissues receive small amounts of 
oxygen, and is an important stimulus for angiogenic factors such as VEGF in vitro 
(Sandner P, et al., 1997), and in vivo (Shweiki D, et al., 1992). Hypoxia-induced 
VEGF production may be the driving force that stimulates the angiogenesis that 
accompanies organ formation during development (Neufeld G, et al., 1999). Some 
cytokines or growth factors such as TGF-β 1 (Frank S, et al., 1995), IL-1β (Li J, et 
al., 1995), IL-1 and PGE2 (Ben-Av P, et al., 1995), and IL-6 (Cohen T, et al., 1996) 
induce an increase in VEGF in different cell lines. Furthermore, the neovascular 
response, and many other related cellular mechanisms necessary for 
angiogenesis, occurs via the action of NO. NO can be triggered by vasoactive 
agents through autocrine and paracrine mechanisms (Davies M, et al., 1995) and 
VEGF increases NO in a dose-time dependent fashion in vascular endothelium 
(Kelly R, et al., 1996). Clear evidence that NO may mediate VEGF action is that the 
NO synthase inhibitors block the effect of VEGF in capillaries (Morbidelli L, et al, 
1996; Whelan I. and Vlahos N, 2000). 
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Studies suggest that angiogenesis plays an active role in cyclic folliculogenesis 
because it is initiated in the early development of the follicle, and a complex 
vascular network is formed within the thecal cell layer during follicular growth (Koos 
R, et al, 1993; Zimmermann R, et al., 2001). VEGF mRNA is present in developing 
follicle GCs during the mid- and late-follicular phases, and mature follicles express 
higher amounts. Levels of VEGF mRNA are correlated with E2 and P4 levels (Doldi 
N, et al., 1997) indicating that angiogenesis triggered by VEGF is important in the 
growth and maintenance of ovarian follicles and corpus luteum. This theory is 
further supported by the fact that blocking VEGF with specific inhibitors causes 
inhibition of the ovulatory process (Zimmermann R, et al, 2001). 
The relationship between VEGF and hCG (Neulen J, et al., 1998; Wang J, et al., 
2002) is extremely important in understanding the development of OHSS because 
hCG administration is the main risk factor involved in the syndrome. In fact, recent 
studies show that GCs from patients who later develop OHSS secrete higher 
amounts of VEGF in response to hCG than those from patients who did not 
develop OHSS (Wang T, et al., 2002). McClure N, et al. (1994) studied the role of 
VEGF in OHSS and concluded that this growth factor is primarily involved in 
increasing VP.  
Animals which lack one of the two VEGF alleles all die before birth because of 
cardiovascular system development defects (Ferrara N, et al., 1996; Carmeliet P, 
et al., 1996; Neufeld G, et al, 1999) thus highlighting the importance of VEGF as a 
central regulator of vasculogenesis and the cardiovascular system. Moreover, 
several studies have demonstrated that disrupting the genes encoding VEGFR-2 
(Shalaby F., et al., 1995) and VEGFR-1 (Fong G, et al., 1995) results in severe 
blood vessel formation abnormalities in homozygous animals (Neufeld G, et al., 
1999). It is known that VEGFR-1 expression is particularly prominent in arterial 
endothelium (Peters K, et al., 1993) whereas VEGFR-2 is increased in capillaries, 
veins, and venules (Millauer B, et al., 1993). VEGFR-1 plays an important role in 
the morphogenesis and structuring of endothelial cells (Fong G, et al., 1995) while 
VEGFR-2 is involved in mitogenesis (Shalaby F, et al., 1995; Gille H, et al., 2001). 
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Several studies have shown that VEGFR-2 is able to regulate angiogenesis and 
VP in endothelial cells whereas VEGFR-1 is not associated with increased VP 
(Waltenberger J, et al., 1994, Gille H, et al., 2001). For this reason it has been 
postulated that the effects of increased permeability are mediated by the binding of 
VEGF to VEGFR-2 and not to VEGFR-1 (Waltenberger J, et al., 1994, Gille H, et 
al., 2001). 
1.10.3. Signal transduction mechanisms 
Although the VEGF receptors are known, the specific endothelial responses 
mediated by VEGFR-1 and VEGFR-2, as well as their downstream signal 
transduction pathways, are not yet fully understood. Cultured endothelial cells 
express both VEGFR-1 and VEGFR-2 making it difficult to evaluate the contribution 
of these receptors to the responses induced by VEGF. However, based on studies 
which determined the enzymatic cascade originating from VEGFR2 signal 
transduction (Esser S, et al., 1998), the current view is that VEGFR-2 is the major 
endothelial cell receptor which transduces the effects of VEGF, as shown in Figure 
4. VEGFR-2 is implicated in most, if not all, aspects of vascular endothelial cell 
biology, and importantly, during development VEGFR-2 is the first specific 
endothelial marker to be expressed on hematopoietic/endothelial progenitors.  
Increases in VP associated with OHSS were significantly inhibited in vivo by 
blocking calcium channel transporters linked to the intracellular space (Bates D.  
and Curry F, 1997). Criscuolo G. and Balleduz  J. (1996) hypothesized that calcium 
entry, promoted by VEGFR-2 signal transduction, induces changes in cell 
morphology by modifying endothelial cell cytoskeletal actin fibers, and that addition 
of VEGF caused the actin fibers in this endothelial monolayer to reorganize leading 
to the formation of gaps between cell junctions. Subsequently, it was determined 
that after VEGF addition, this reorganization occurs not only in cytoskeletal actin 
fibers, but also in intercellular junction proteins, such as occludin and zonula 
occludens-1 (ZO-1), which help to maintain tissue cohesion and stability (Kevil C, 
et al., 1998). These findings indicate that the cell junctions were missing, allowing 
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the formation of inter-cellular pores which facilitate leakage. Other reports support 
these findings, showing that the cell junction stability is dependent on the 
phosphorylation-dephosphorylation reactions promoted by VEGF (Antonetti D, et 
al., 1999). 
Given the role of VEGF in modulating both VP and angiogenesis, there has been 
great scientific effort to develop and establish several strategies which can act on 
VEGFR-2 transduction pathways in order to inhibit VEGF secretion. 
 
 
 
 
Figure 4. A simplified scheme showing the signaling events initiated in endothelial cells upon 
VEGFR-2 activation. VEGF binding to the VEFGR-2 in the endothelium requires VEGFR-2 
autophosphorylation in order to activate it. Phospholipase C (PLC) is activated which releases 
diacylglycerol (DAG) and inositol triphosphate (IP3) as second messengers. These intermediaries 
activate different pathways, which leads to increased vascular permeability. 
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1.10.4. Vascular endothelial growth factor/receptor-2 pathway inhibitors 
VEGF binding to VEGFR-2 leads the development of new blood vessels which 
often adhere to and nourish tumor cells. In order to block this union, different 
VEGF/VEGFR-2 pathway inhibitors have been studied. In 1995, rodent anti-
VEGFR-2 neutralizing antibodies were generated, of which DC101 was the most 
used (Rockwell P, et al., 1995). Subsequently, both DC101 and cp1c11 (Zhu Z, et 
al., 1999) were modified for clinical use (humanized antibodies), marking the 
beginning of a new type of cancer treatment. Other strategies were used to 
generate peptides which would prevent VEGF from binding to the VEGFR-1 and 
VEGFR-2 receptors in the hope that these could lead to the development of 
pharmacologically useful VEGF antagonists (Wayne J, et al., 1998).  
Although these antibodies were specifically designed to inhibit the growth of new 
blood vessels which could supply nutrients to tumor cells, their efficacy in 
specifically modifying VP has not been assessed. Suramin was originally used as 
an antitrypanosomal drug in 1916, but recently new properties, such as its ability to 
decrease VP have been uncovered, although its effect if altering mitochondrial 
genetic information makes it too dangerous to use as a therapeutic agent for 
pregnant women with OHSS. Furthermore, its permeability-blocking effects are not 
specific, and it tends to decrease endothelial mitogenicity. ZD4190 also 
represented a step forward in inhibitor development, not by increasing blocking 
ability but because the compound could be administered orally (Wedge S, et al., 
2000). However, it is not a specific endothelial permeability inhibitor so its future 
use will depend on appropriately modifying it to be more specific.  
Since then, a wide range of specific VEGFR-2 inhibitors have been developed 
(Strawn L, et al., 1996), such as SU5416, which inhibits VEGFR-2 phosphorylation, 
preventing signal transduction and therefore also the enzymatic cascade leading to 
significant increases in VP (Fong T, et al., 1997). This inhibitor was originally 
designed as an antitumor agent; however its most important effect is its ability to 
inhibit endothelial cell permeability in rodents harboring a tumor cell line. SU5416 is 
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an excellent candidate for blocking or inhibiting the in vivo VP which characterizes 
OHSS, because: 1) it decreases the endothelial permeability in rodents without 
apparent toxic effects; 2) it is specific for VEGFR-2 without cross reacting with 
other receptors in the same family such as VEGFR-1; 3) it has a high affinity for its 
receptor.  
Gómez et al. demonstrated that the increase in VP brought on by hCG 
administration coincides with ovarian production and expression of VEGF and 
VEGFR-2, and used SU5416 in an animal OHSS model to counteract the 
increased VP caused by hCG administration (Gómez R, et al., 2002 and 2003). 
Despite this being the first study that established a specific OHSS therapy, there 
are two drawbacks which mean it is not suitable for humans, and is mutually 
exclusive to ART. First, the high toxicity of commercial VEGFR-2 inhibitors: for 
example, SU5416 brings on pulmonary hypertension and has thromboembolic 
effects (Taraseviciene-Stewart L, et al., 2001; Kuenen B, et al., 2003; Glade-
Bender J, et al., 2003). Second, the absolute functional dependence of the ovary 
(Wulff C, et al., 2001; Pauli S, et al, 2005; Zimmermann R, et al, 2001 and 2003) 
and uterus (Rockwell L, et al., 2002; Heryanto B, et al, 2003) on VEGF secretion, 
and its requirement for maintaining pregnancy. Nevertheless, these studies 
demonstrated that blocking VEGFR-2 does decrease the excessive VP found in 
OHSS, and so based on this knowledge, new strategies which block increases in 
VP through VEGFR-2 or its signal transduction intermediates can be developed as 
effective and tolerable therapeutic treatments in humans. 
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1.11. ALTERNATIVE STRATEGIES FOR REPLACING COMMERCIAL 
VEGFR2 INHIBITORS TO PREVENT OHSS 
In an attempt to avoid OHSS-associated angiogenesis, genes that were 
upregulated and downregulated in the ovaries of OHSS and control rats were 
studied (Gómez R, et al, 2003); only genes coding for target proteins that might 
have been involved in regulating VP were taken into account, resulting in the 
identification of 72 genes (including VEGF and prostaglandins) in the OHSS group 
which were possible OHSS mediators. From these genes, four were selected for 
further study based on a literature review: squalene epoxidase (SQE), tartrate-
resistant acid phosphatase (TRAP), insulin-induced growth response protein (CL-
6), and (TH). Interestingly TH, an enzyme present in dopaminergic cells and 
involved in dopamine (Dp) synthesis (Fujisawa H, et al, 1987; Zigmond M, et al., 
1989), was downregulated in rat OHSS ovaries. Given that Dp inhibits the release 
of LH (Chang J, et al., 1990), which in turn is implicated in the development of 
OHSS when its expression is increased, a possible role for Dp in the development 
of OHSS via LH modulation was considered. However, a potential alternative 
mechanism for Dp in OHSS modulation was shown in which Dp might act as a 
modulator of VEGFR2 function (Basu S, et al., 2001). Given the paramount 
importance of VEGFR2 in the development of OHSS D2-ags were considered as 
possible candidates for OHSS treatment via VEGFR2.  
The following section contains a detailed description of our current understanding 
of the dopaminergic system which will facilitate the subsequent comprehensive 
understanding of modulation of the VEGF/VEGFR2 system by Dp. 
1.12.   DOPAMINE AND DOPAMINERGIC RECEPTORS 
Dopamine or 3,4-dihydroxyphenethylamine (Dp) is a neurotransmitter which acts 
as a chemical messenger that exerts its function by transmitting signals in the brain 
and other vital areas, and has been described in both humans and animals. 
Dopaminergic receptors belong to a class of G protein-coupled receptors, of which 
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Dp is the primary endogenous ligand. There are five subtypes: D1, D2, D3, D4, and 
D5, which are organized into two families (D1-like or D2-like); the D1 and D5 
receptors are members of the D1-like family, whereas the D2, D3, and D4 receptors 
are members of the D2-like family. The biological function and location of the 
different Dp receptor subtypes still remains unclear (Vallone D, et al., 2000), 
although the presence of D2 receptors has been described on ECs (Basic F, et al., 
1991), lymphocytes (Basu S. and Dasgupta, 2000), and platelets (Emerson M, et 
al., 1999). 
Dp controls a variety of functions including locomotor activity, cognition, emotion, 
positive reinforcement, food intake, and endocrine regulation (Missale C, et al, 
1998). This catecholamine also exerts an inhibitory action on Prolactin (Prl) 
secretion (Lacasse P, et al., 2012; Freeman M, et al., 2000), which strongly inhibits 
lactation when it is suppressed (Flint D. and Gardner M, 1994; Taylor J. and 
Peaker M, 1975), therefore Dp administration has previously been used in the clinic 
to inhibit lactation. 
1.13. THE DOPAMINERGIC SYSTEM IN THE OVARY 
It is known that there are high levels of Dp both in FF and human ovarian biopsies 
(Bodis J, et al., 1992; Lara H, et al., 2001), for this reason its function within the 
ovary has been questioned: if Dp has a specific ovarian function, a requisite for its 
action is the presence of functional receptors. A study carried out by Rey Ares’s 
group described the presence of D1 and D5 (D1-like family) and D2, D4 (D2-like 
family) but not D3 on human GCs (Rey-Ares V, et al., 2007), and of the Dp 
receptors found on them, D2 was had the highest expression. 
Although GCs do not synthetize Dp (Mayerhofer A, et al., 1998), these cells are 
able to absorb it from the circulation, store it, and metabolize it (Greiner M, et al., 
2008). Taking this knowledge and the findings provided by Rey Ares’s study 
together, Dp might act through the D1, D2, D4, and D5 pathways which are co-
expressed on GCs, therefore suggesting a complex role for Dp in the regulation of 
ovarian processes. Despite these data, the role of the dopaminergic system in the 
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human ovary remains unknown, although its potential role in modulating OHSS 
might perhaps be inferred by comparision of how the dopaminergic system 
regulates VEGF in other analogous organs, as described below. 
1.14.  MODULATION OF THE VEGF/VEGFR2 SYSTEM BY DOPAMINE 
Basu et al. were the first to propose a relationship between the dopaminergic 
sytem and VEGF/VEGFR2 system after observing that angiogenesis was inhibited 
by Dp in several tumor types (Basu S. and Dasgupta, 2000). A year later, the same 
group confirmed this hypothesis by showing that Dp inhibited angiogeneis and VP 
induced by VEGF-secreting ovarian tumor cells injected into mice (Basu S, et al., 
2001). This group reported that EC VEGFR2 phosphorylation was decreased by 
D2-ags which was very likely due to their induction of VEGFR2 internalization, 
presumably by endocytosis, thus leaving less cell surface-VEGFR2 able to interact 
with VEGF (Basu S, et al., 2001). In an attempt to improve the characterization of 
this molecular mechanism, a subsequent study carried out by Sarkar C et al. 
showed that inhibition of VEGFR2 phosphorylation by Dp altered MAPKs, src, and 
FAK (Sarkar C, et al., 2004). Finally, in 2009 an in vitro study by Sinha showed that 
D2-ags were able to decrease VEGFR2 phosporylation by inactivating specific 
tyrosine sites (Sinha S, et al., 2009). 
Subsequently, Cristina C. et al. investigated the expression, localization, and 
function of VEGF in pituitary hyperplasia in D2-knockout female mice. The authors 
observed that the pituitary expresion of VEGF protein and mRNA were increased in 
these mice when compared to wild-type mice. Wild-type mice also showed an 
increase in pituitary VEGF expression and the levels of Prl released when they 
were treated with a D2-antagonist (Cristina C, et al., 2005). These observations 
suggested that the presence of D2 could inhibit or regulate VEGF production and 
secretion and thereby reduce the availability of VEGF. Therefore, this study 
suggested that two mechanisms by which the dopaminergic system (Dp/D2) 
inhibits the increases in VP at the root of OHSS may coexist. The first mechanism 
might involve direct action on VEGFR2 by D2 to inhibit its phosphorylation. The 
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second mechanism is likely to be an indirect interaction between D2 and VEGFR2 
in such a way that D2 activation might inhibit VEGF secretion. In order to determine 
the potential role of these mechanisms further studies in human and animal models 
have been performed, the most relevant of which are detailed in the following 
section. 
1.15.  OHSS INHIBITION STUDIES WITH DOPAMINERGIC AGONISTS 
1.15.1. Studies in animals 
High doses of D2 agonists (D2-ags) have been demonstrated to simultaneously 
block tumor-related angiogenesis and VP in a mouse cancer model by interfering 
with VEGF/VEGFR2 signaling (Basu S, et al., 2001). Based on this finding Gómez 
et al. (2006) hypothesized that it might be possible to use the Dp/D2 pathway to 
interfere with VEGF/VEGFR2-mediated VP without interfering with angiogenesis. In 
order to corroborate this hypothesis, the authors conducted a study using Prl-
supplemented OHSS rats which were treated with D2-ags; this demonstrated that 
administration of low doses of the D2-ag Cb2 in immature rats prevented increases 
in VP without affecting angiogenesis. Therefore, these findings suggested, for the 
first time, that low-dose Cb2 might provide a new, specific, and nontoxic approach 
to the treatment of diseases such as OHSS, which require VEGF/VEGFR2-
mediated VP to be inhibited without affecting angiogenesis. 
1.15.2. Studies in humans 
Following on from these promising animal-study findings (Gómez R, et. al., 2006), 
and given that D2-ags have been widely used in the clinical treatment of human 
pathologies such as hyperprolactinemia (even in pregnant women) without toxicity 
or teratogenic effects, further studies were developed to evaluate the effectiveness 
of Dp as an OHSS treatment in humans. The first such study, aimed to prevent 
increases in VP and hemoconcentration (both signs of OHSS in humans), was a 
prospective trial carried out by our group in which MRI (magnetic resonance 
imaging) was used for the first time as a non-invasive method to quantify VP. In 
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this study oocyte donors received 0.5 mg/day of Cb2 for 8 days, starting on the 
same day that hCG administration was started (Álvarez C, et al., 2007a). Authors 
could confirm that D2-ags blocked the increases in hemoconcentration and VP 
triggered by hCG, thus reducing the incidence of moderate OHSS. 
Although these findings were very promising because they showed that D2-ags 
had the same effect in humans as previously observed in animal OHSS models 
(Gómez R, et al., 2006), it was not possible to determine if the doses administered 
affected angiogenesis and would have therefore also attenuated reproductive 
function. Therefore a subsequent study was undertaken by Álvarez et al. to 
investigate the effects of Cb2 on implantation and related pregnancy rates in 
patients with a risk of OHSS treated with Cb2 or in a control group without a risk of 
OHSS, showing that there were no differences in the fertilization, implantation, or 
pregnancy rates between the two groups (Álvarez C, et al., 2007b) thus suggesting 
that Cb2 can prevent OHSS without affecting clinical outcomes.  
Encouraged by both the efficacy and lack of toxic and/or teratogenic effects of D2-
ags, subsequent studies with Cb2 were performed by several groups. Carizza et al. 
replicated the results obtained by Álvarez et al. in a prospective randomized study 
which evaluated the role of Cb2 in decreasing the incidence of OHSS in high-risk 
patients. They showed that women with a risk of OHSS did not develop early 
OHSS when were treated with Cb2 and neither implantation nor abortion rates 
were altered, corroborating that administration of D2-ags can affect VP without 
compromising angiogenesis. However, similar to our previous study, Cb2 
administration also failed to prevent late OHSS (Carizza C, et al., 2008). Other 
recent studies have revealed similar findings in which treatment with Cb2 
prevented the early-onset of OHSS in 50% of women at risk, but that Cb2 was 
ineffective at preventing the late-onset form of the syndrome (Youssef M, et al., 
2010; Hosseini MA, et al, 2011; Tang H, et al., 2012; Seow KM, et al., 2013; 
Esinler I, et al., 2013; Leitao VM, et al 2013). Moreover, most studies using D2-ags 
other than Cb2, such as bromocriptine (Sherwal V, et al., 2010; Spitzer D, et al., 
2011) and quinagolide (Busso C, et al., 2010) also found similar results.  
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In spite of the potential benefits of Cb2 in preventing early OHSS, there is no 
consensus on the choice of the best agonist dose to use. One study using Cb2 
stated that at lower doses it reduces the incidence of OHSS as much as at higher 
doses (Shaltout A, 2012). However, a study with a different D2-ag (Quinagolide) 
clearly showed a dose dependent effect on OHSS prevention (Busso C, et al., 
2010). In this study 182 women with a risk of OHSS were distributed into 4 groups: 
the control group (placebo) and the study groups treated with 50 mg/day, 100 
mg/day, or 200 mg/day of quinagolide. The results showed that the incidence of 
OHSS was 23% in the placebo group, whereas it was significantly lower at 12%, 
13%, and 4% respectively in the treated groups. Moreover, at the highest dose 
there were no incidences of severe OHSS.  
1.16. IMPLICATIONS OF THE DOPAMINERGIC AND VEGF SYSTEMS 
ON CORPUS LUTEUM REGULATION IN PHYSIOLOGICAL AND 
PATHOLOGICAL CONDITIONS 
It is known that women suffering from PCOS overexpress and oversecrete VEGF 
during the luteal phase after the induction of ovulation (Kamat B, et al., 1995; 
Agrawal R. et al., 2002; Neulen J, et al., 1995), indicating that VEGF is deregulated 
in these patients. Moreover, elevated Prl levels (Hernandez I, et al., 2000) have 
also been observed in PCOS which could indicate a reduced dopaminergic tone in 
these patients. In the light that the Dp/D2 pathway modulates VEGF production 
and secretion and is therefore implicated in PCOS, this thesis hypothesized that 
deregulation of the VEGF/VEGFR2 pathway in women with PCOS might be at 
least be partially due to abnormalities in the Dp/D2 system. To test this hypothesis 
our main goal was to ascertain whether activation of the dopaminergic system can 
modulate the VEGF/VEGFR2 system in human GCs and ECs. We also sought to 
evaluate whether there were significant differences in the dopaminergic tone in 
healthy vs. PCOS patients which could explain their susceptibility to developing 
OHSS. 
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Firstly it was necessary to isolate GCs and ECs in order to perform our in vitro 
studies. However, we did not have an optimized isolation protocol. There was only 
one previous publication about EC isolation (Ratcliffe K, et al., 1999), but several 
GC isolation methods had been described. Therefore, the efficiency of these 
different GC isolation methods were compared in order to determine the optimal 
method for obtaining the highest number of GCs without compromising cell purity 
or integrity. The process of attaining a GC isolation method and the evaluation of 
the interaction of the dopaminergic system (Dp/D2) and VEGF/VEGFR2 system in 
physiological and pathological conditions on these isolated cells constitutes the 
main body of this thesis. 
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2.  HYPOTHESIS 
It is known that development of OHSS is caused by increased VP which is 
mediated by the VEGF/VEGFR2 system. Regulation of ovarian VEGF production, 
secretion, and action is dependent not only on gonadotropins but also on other 
factors, among them D2.  
Therefore we hypothesized that D2-ags can inhibit increases in VP by inhibiting 
either VEGFR2 phosphorilation or VEGF production. This hypothesis suggests the 
existence of a dopaminergic system inside the ovary which would determine each 
woman’s individual susceptibility to changes in the VP of their ovaries caused by 
the VEGF/VEGFR2 regulation system. Considering this hyphotesis, we postulated 
that difference or deficiencies in expression or regulation of dopaminergic tone may 
be associated with the deregulation of the VEGF/VEGFR2 system in the ovary and 
thereby also with an individual’s susceptibility to developing ovarian-dependent 
pathologies such as OHSS. 
In this context, given the importance of VEGF in OHSS, and since its regulation is 
mediated by Dp, we hypothesized that in patients susceptible to OHSS, such as 
PCOS patients, VEGF/VEGFR2 is deregulated because these patients have a 
deregulated dopaminergic tone. 
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3. OBJECTIVES 
To ascertain whether activation of the dopaminergic system (Dp/D2) is able to 
modulate the VEGF/VEGFR2 system in GCs and ECs and to evaluate whether 
there were significant differences in the dopaminergic tone in healthy vs. PCOS 
patients which could explain their susceptibility to developing OHSS. 
3.1. SPECIFIC OBJECTIVES 
1. To identify ovarian populations with an active dopaminergic system by 
immunolocalizing D2 in these cells. 
 
2. To compare the efficiency of different FF-derived cell isolation methods in 
order to determine which method allows the highest number of interested cells 
to be obtained for in vitro culture without compromising their cellular purity. 
 
3. To determine whether the dopaminergic system modulates the secretion of 
VEGF and VEGFR2 activation in in vitro cultured FF-derived D2 expressing 
cells. 
 
4. To compare the D2 expression pattern in ovarian cell populations over the 
different phases of the menstrual cycle in both physiological and pathological 
conditions.    
 
5. To asses the Dp/D2 and the VEGF/VEGFR2 system in FF-derived cells from 
healthy vs. PCOS patients in order to analyze whether there are differences in 
the dopaminergic tone between them. 
 
 
 
 
  64   
  
 
 
 
  
65 
 
 
 
 
 
4. MANUSCRIPTS 
 
 
 
 
 
 
 
 
 
 
 
  66   
  
 
  
67 
 
 
 
 
 
4.1. MANUSCRIPT-I 
 
 
 
 
 
 
 
 
 
 
 
  68   
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
69 
 
 
  70   
  
  
71 
 
 
  72   
  
 
  
73 
 
 
  74   
  
 
  
75 
 
 
  76   
  
 
  
77 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  78   
  
 
 
 
  
79 
 
 
 
 
 
4.2. MANUSCRIPT-II 
 
 
 
 
 
  80   
  
 
 
 
 
 
 
 
 
 
  
 
81 
 
 
  82   
  
 
  
 
83 
 
 
  84   
  
 
  
 
85 
 
 
 86 
 
 
  
 
87 
 
 
 88 
 
 
  
 
89 
 
 
 90 
 
 
  
 
91 
 
 
 92 
 
 
  
 
93 
 
 
 
 
 
4.3. MANUSCRIPT-III 
 
 
 
 
 94 
 
 
 
 
 
 
  
 
95 
 
 
 96 
 
 
  
 
97 
 
 
 98 
 
 
  
 
99 
 
 
 100 
 
 
  
 
101 
 
 
 102 
 
 
  
 
103 
 
 
 
 
 
 
 
 104 
 
 
  
 
105 
 
 
 
 
 
5. RESULTS 
SUMMARY 
 
 
 
 
  
106 
 
 
 
                                                                                                RESULTS SUMMARY                                                                                             
107 
 
5. RESULTS SUMMARY  
 
I. Efficiency and purity provided by the existing methods for the isolation of 
luteinized granulosa cells: a comparative study. 
Human Reproduction 2012; 27(6):1781-9 
 
Ferrero H, Delgado-Rosas F, García-Pascual CM, Monterde M, Zimmermann RC, 
Simón C, Pellicer A, Gómez R. 
 
In order to determine the dopaminergic effects on the production of VEGF in 
physiological and pathological conditions, the individual characteristics of each 
patient had to be preserved and therefore, pools of LGCs could not be used. 
Hence the highest possible number of LGCs needed to be obtained from each 
patient for our in vitro cultures without compromising their purity.  
 
Several LGC isolation methods were described and among them were methods 
which allowed a very pure population to be obtained, however it yielded very few 
cells; other methods yielded a large number of cells but compromised the purity of 
the LGC population. In this first study, we aimed to ascertain which of the existing 
methods allowed the highest number of LGCs to be obtained without compromising 
their purity or viability for our subsequent in vitro cultures. 
 
LGCs which were destined for use in our in vitro studies had to be obtained during 
the oocyte retrieval process, an invasive method that may penetrate vascularized 
structures. Hence, the cells obtained from the FF obtained in these retrievals are 
contaminated with vascular components, resulting in a heterogeneous cell 
population containing LGCs, CD45+ immune cells, erythrocytes, and lower 
quantities of other cell types such as ECs and epithelial cells. The presence of 
immune cells in the FF is especially critical, as these cells can directly influence the 
results obtained in subsequent in vitro studies with LGCs. Therefore, isolation 
techniques had to be applied in order to establish pure, or almost pure, in vitro LGC 
cultures so that the specific role of these cells in follicle development and ovarian 
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function could be inferred. Given that GCs do not express a specific marker which 
allows their isolation by positive discrimination we instead compared the efficiency 
of the different depletion methods described for the LGC isolation. 
 
The main stratergies currently used for the depletion of unwanted cells can be 
classified into two main groups according their restrictiveness: (i) highly specific 
depletion strategies based on immunological recognition of specific contaminating 
cell markers and (ii) non-specific depletion strategies based on the differential 
physical properties of the contaminating and desired cells. In order to determine 
the best isolation method, each of the FF samples was pooled into two aliquots: 
named ‘C’ (Control) or ‘E’ (Experimental). The control aliquot was used as an 
internal standard control against which the experimental aliquots were compared 
after the specific isolation method was complete. The different methods used in this 
comparative study were described in manuscript-I. Both control and experimental 
aliquots were analyzed by flow cytometry to evaluate the contaminating cell 
population, which was identified as CD45+ cells. 
 
The analysis of the flow cytometry data revealed that depletion techniques based 
on the recognition of specific cell markers reduced the CD45+ contaminating cells 
by 90-100%. Dynabeads and MACS (magnetic-activated cell sorting) methods 
were highly efficient at reducing CD45+ cell contamination, with no significant 
differences between them, as shown in Table II in manuscript-I. However, as 
expected, FACS (fluorescence-activated cell sorting) was the most effective of 
these methods at reducing the immune cell population, with just under 0.1% 
CD45+ contaminating cells detected in the experimental aliquots. However, despite 
the high purity of the LGCs obtained, we observed a drastic reduction in the 
number of LGCs recovered by these depletion techniques when compared with 
other methods. Although we expected that FACS would give the highest recovery 
of viable cells, the data obtained from flow cytometric analysis showed that LGC 
recovery was less than 20% as almost 50% of cells died during the sorting 
process. Therefore, despite providing the highest percentage of pure LGCs, the 
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FACS process led to a low cell viability, which suggests that LGCs are very 
sensitive to cell sorting. As a consequence FACS resulted in a lower LGC recovery 
rate than the other methods. 
 
Regarding the aggregation and flask methods (which are usually based on the 
differential adhesive and aggregative properties of immune cells and LGCs 
respectively and so require very little manipulaton), a high percentage of viable 
LGCs was obtained, as shown in Table II in manuscript-I. Therefore, unexpectedly 
these methodologies gave the highest viable LGC recovery when compared to all 
of the other protocols tested (aggregation: 73.20% ± 6.2; flask 51.63% ± 12.6). The 
main concern with these techniques was the purity of the cell population obtained 
from them. Unfortunately for our purposes the high percentage of CD45+ cells 
observed in samples obtained by these methods meant that they were not suitable 
for our purposes. In particular, the aggregation method provides the lowest 
percentage of CD45+ reduction, probably because it involved the subjective 
judgement of the person performing the separation. These methodologies were not 
able to sufficiently discriminate between different cell populations and as result they 
are less effective than the other methods at selecting out contaminating CD45+ 
white cells. 
 
Therefore, depletion techniques based on the recognition of specific cell markers 
could not be used for our purposes due to the low number of cells obtained, and 
neither could techniques based on the physical/chemical characteristics of the cells 
because of their poor ability to discriminative out contaminanting cells. We found 
an alternative cell strainer method for LGC isolation method in the literature 
(Richardson MC, et al., 2009). This methodology is based on the fact that LGCs 
form large cell aggregates in such a way that clusters can be retained by 40 µm 
cell strainers while erythocytes and other blood contaminants pass through the 
membrane. We assayed this methodology but with some modifications to improve 
it: the LGC suspension was not incubated at 37º C for 3-4 h before being aspirated 
them through pipettes and they were not subsequently centrifuged after break up.  
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Our results showed that the cell strainer method gave a high percentage of LGCs 
recovery (70%) with a viability of 92.75%. Moreover, flow cytometry revealed that 
only 3.29% of the cells in the suspension were CD45+ cells, as shown Table II in 
manuscript-I. Since any isolation method which obtains a less than 5% 
contamination rate is considered acceptable, strainer method was considered to be 
the best for obtaining the highest number of LGCs without compromising their 
purity, and therefore it was used in all the studies described in this thesis. 
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II. Dopamine receptor 2 activation inhibits ovarian Vascular Endothelial 
Growth Factor secretion in vitro: implications for treatment of Ovarian 
Hyperstimulation Syndrome with Dopamine receptor 2 agonists 
Fertility and Sterility 2014; 
Hortensia Ferrero PhD, Carmen M. García-Pascual PhD, Raúl Gómez PhD, Francisco 
Delgado-Rosas PhD, Omar  Cauli PhD, Carlos Simón MD, Francisco Gaytán MD, 
Antonio Pellicer MD. 
 
In a previous study from our group (Gómez R, et. al., 2006) we observed that the 
administration of D2-ags to a prl-supplemented OHSS rat model blocked the 
OHSS-associated increase in VP and was associated with a decrease in ovarian 
VEGFR2 phosphorylation levels. Subsequently, studies from our group verified that 
the D2-ag Cb2 reduced the incidence of moderate OHSS in humans by inhibiting 
the increase of ovarian VP (Álvarez C. et al., 2007). Given that the presence of D2 
on human LGCs seemed restricted to some patients (Álvarez C, et al 2007) this 
study originally aimed to ascertain whether this phenomenon was associated with 
the differential efficacy of these drugs in preventing OHSS in some patients. The 
efficacy of treatments seemed to be restricted to 50% of patients for early OHSS 
with a total inefficacy in preventing OHSS during the late stage of CL but not late 
OHSS. Hence, the main initial goals of this study were: 
 
a) To evaluate whether D2-ags modulate the VEGF/VEGFR2 system in human 
ovarian populations which express D2. 
b) To ascertain whether some patients express ovarian D2 while others do not, 
and whether this could be a plausible explanation for the apparently restricted 
efficacy of these drugs in preventing early OHSS in some patients. 
c) To ascertain whether ovarian D2 expression abruptly declines or totally 
vanishes during the late-lutal phase as a plausible explantation for the total 
inefficacy of D2-ags in preventing OHSS during the late CL stage.  
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To pursue these goals we immunolocalized D2 in human ovarian tissue samples 
taken from different cycle phases under physiological conditions. We observed 
that, although there were different levels of staining, D2 was consistently 
expressed in all of our human ovarian samples. Therefore, it was more likely that 
differential D2 expression between patients (some patients expressing it while 
others not at all) was related to the differential efficacy of these drugs in preventing 
early OHSS.  
 
To our suprise we observed that D2 expression was not detected in ovarian ECs 
as we had expected. This meant that the effects of D2-ags on reducing ovarian VP 
were not mediated directly by acting on VEGFR2 expressed on ovarian ECs but 
rather via an alternative mechanism. When trying to establish a link between the 
dopaminergic system and VEGFR/VEGFR2 system in the ovary we observed that 
D2 staining was restricted to: macrophages, LGCs, and theca cells, as shown in 
Figure 4 A-C in manuscript-II. Due to ovarian ECs do not express D2 and the 
number of theca lutein cells obtained from FF was not sufficient for in vitro culture, 
we had to limit our subsequent in vitro studies to LGCs as the only D2-expressing 
cell population which we could easily and consistently obtain from FF. 
 
In order to determine whether (and how) VEGF production by LGCs might be 
modulated by the dopaminergic system, LGCs were cultured in the 
presence/absence of different doses of Cb2 and the D2-antagonist L-741.625 for 
three days. We observed that when Cb2 was assayed alone it inhibited VEGF 
secretion in a dose-dependent fashion whilst L-741.625 had no effect when 
assayed under similar conditions. Interestingly, the decrease in VEGF initiated by 
D2-ags was partially abated when equal doses of the D2-ant were administered 
concomitantly, as shown Figure 1 in manuscript-II.  Therefore, it is likely that the 
VEGF dose-dependent inhibition exerted by D2-ags in LGCs was due to a D2-
mediated effect. 
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Subsequently we assessed whether the capacity of LGCs to inhibit VEGF secretion 
in response to D2-ags depends on the amount of D2 specifically expressed on the 
cell surface of each patient. Therefore, we determined the amount of D2 
expression on the surface of LGCs treated with different D2-ag concentrations. We 
observed that at lower Cb2 concentrations (20-60 µM) there was a clear correlation 
between the percentage of VEGF inhibition and LGC surface D2 expression. 
However, this correlation tended to be extinguisted with increasing doses of the 
D2-ag to the point of extinction at the highest doses (80-100 µM). In this latter 
scenario even LGCs with very low levels of D2 expression showed VEGF inhibition 
similar to that shown by samples with high levels of D2 expression (Figure 2 in 
manuscript-II). These results suggest that at low D2-ag doses the LGCs expressing 
a higher amount of D2 on their surface are more efficient than LGCs with a low D2 
density at inhibiting VEGF secretion. In contrast, this D2-dependent ability shown 
by LGCs could be counteracted by administering higher quantities of D2-ag. 
Overall this experiement suggested that perhaps patients with higher LGC surface 
D2 expression might be more likely to respond successfully to D2-ag therapies 
aimed at preventing OHSS than those with a low D2 LGC surface expression.  
 
In our subsequent experiment we wanted to determine the molecular mechanism 
by which Dp exerts its action on VEGF secretion in LGCs. Unfortunately, we were 
unable to identify the D2 pathway involved in VEGF secretion, but we discovered 
that inhibition of VEGF secretion by Cb2 was exerted postranscriptionally and not 
at the transcriptional level. Moreover, because we observed the same results both 
in presence and absence of hCG we concluded that D2-ags decrese VEGF protein 
secretion without interfering with hCG-mediated pathways. 
 
To reach these conclusions we measured VEGF mRNA expression and VEGF 
protein secretion simultaneously in LGCs cultured with or without hCG in the 
presence/absence of Cb2 for 24, 48 or 72 hours. In presence of this D2-ag there 
was a clear reduction in VEGF protein secretion; in contrast, this reduction was not 
observed in VEGF mRNA levels in D2-ag-treated vs. non-treated LGCs over this 
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time course, as shown Figure 3 in manuscript-II. The same results were observed 
in the presence or absence of hCG.  
 
As we mentioned in our hypothesis, the inefficacy of D2-ags in preventing late 
OHSS might be due to the abrupt decrease in D2 expresion in CL during the late 
stage, in which appears OHSS. We characterized and quantified D2 expression in 
human ovarian sections over the whole ovarian cycle, observing that D2 
expression was the strongest in theca cells and remained unchanged throughout 
the luteal phase. In contrast, we observed cyclical variations in D2 intensity and 
distribution in GCs: staining was weak at the preovulatory phase but substantially 
increased and peaked during the early luteal phase, as shown in Figure 4 A in 
manuscript-II. Subsequently, LGC staining started to decrease as the age of the CL 
advanced, until its expression was nearly abolished at the later CL stages, as 
shown in Figure 4 B-C in manuscript-II. On the basis of these findings we suggest 
that D2-ags might not prevent late OHSS because LGC surface D2-expression at 
this stage of the luteal phase is decreased and therefore is not sufficient to inhibit 
VEGF secretion to the extent by which the increase in VP is prevented. 
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III. Evidences for the existence of a low dopaminergic tone in Polycystic 
Ovarian Syndrome: Implications for OHSS development and treatment. 
Journal of Clinical Endocrinology & Metabolism (JCEM) 2011; 96(8):2484-92 
 
Ferrero H, Gómez R, Delgado-Rosas F, Gaytán M, Morales C, Zimmermann RC, Simón C, 
Gaytán F, Pellicer A. 
 
The finding that D2 is expressed in theca and GCs throughout the luteal phase in 
normal human ovaries (manuscript-II) lent further support for an intraovarian 
regulatory role for the Dp/D2 pathway in OHSS. Moreover, the dose-dependent 
inhibition of LGC VEGF production and secretion mediated by Cb2 (manuscript-II) 
suggested that the ovarian VEGF/VEGFR2 system can be modulated by the 
ovarian dopaminergic system in the ovary, and that this inhibition also directly 
correlates with the amount of D2 expressed by LGCs. Given that the dopaminergic 
tone in women with PCOS might be deregulated, as shown by the high percentage 
of them with elevated prl levels, and that the VEGF/VEGFR2 system also seems to 
be altered in PCOS patients, we hypothesized that deregulation of the 
VEGF/VEGFR2 pathway in PCOS women might at least be partially due to Dp/D2 
pathway abnormalities. 
 
To test this hypothesis we analyzed the expression of D2 on dated, archived, 
PCOS and non-PCOS ovaries obtained at different stages of the menstrual cycle. 
We observed D2 expression in the granulosa layer of primordial, primary, and 
preantral follicles in non-PCOS ovaries, as shown in Figure 1 A-D in manuscript-III, 
whereas most small follicles in PCOS ovaries lacked, or showed barely detectable, 
D2 expression, as shown in Figure 1 E-I in manuscript-III. Decreased D2 
expression in PCOS ovaries seemed to be specific to GCs in small follicles and to 
the theca cell layer in antral follicles; because macrophages present in atretic 
follicles showed intense expression, similar to that found in cycling ovaries, as 
shown in Figure 1 J in manuscript-III. The theca layer of the antral follicles in PCOS 
ovaries showed significantly lower D2 expression and higher vascularization 
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(CD34+) than normal cycling ovaries, as shown in Figure 2 in manuscript-III. These 
differences were particularly prominent in luteinized follicles, as shown in Figure 3 
in manuscript-III. 
 
We subsequently aimed to ascertain whether VEGF/VEGFR2 pathway 
deregulation might at least be partially due to abnormalities in the Dp/D2 pathway 
in PCOS women. Therefore, we performed functional studies by culturing hCG-
stimulated LGCs isolated from PCOS and non-PCOS patients with Cb2 at 
concentrations of 0, 20, 40, 60, 80, or 100 µM for 72 h. In the absence of the D2-ag 
LGCs from both groups secreted similar amounts of VEGF in response to hCG, as 
shown in Figure 4A in manuscript-III. However, when Cb2 was added to the culture 
media the VEGF secretion decreased in a dose-dependent fashion with maximal 
inhibition in both groups at the highest Cb2 dose (100 µM). However, the most 
interesting finding was that the inhibition of VEGF secretion seemed to be more 
prominent in non-PCOS than PCOS patients.  
 
These results suggested that LGCs from non-PCOS patients are more efficient 
than those from PCOS women at decreasing VEGF secretion in response to D2 
activacion. In order to confirm our suspicions, we analyzed the percentage of 
VEGF inhibition in these samples, showing that LCGs from PCOS were less 
efficient at decreasing VEGF, as shown in Figure 5 in manuscript-III. Additionally, 
after compensating for decreased dopaminergic tone in PCOS patients, we 
observed that LGCs from PCOS samples secreted lower amounts of Dp than those 
from non-PCOs ovaries, as shown in Figure 4D in manuscript-III. Interestingly, the 
secretion of 3,4-Dihydroxyphenylacetic acid (DOPAC; the first product derived from 
Dp metabolism) was significantly increased in PCOS sample cells, as shown in 
Figure 4E in manuscript-III. These findings suggested that not only is the amount of 
Dp reduced but in addition this metabolite is also more quickly metabolized in 
PCOS patients, supporting the notion that dopaminergic tone and metabolism are 
deregulated in PCOS women.  
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Overall, the evidence complied in thesis suggests that the dopaminergic tone is 
deregulated in PCOS patients and that this factor might explain, at least in part, the 
deregulated expression of VEGF in these women and thus also the higher 
susceptibility of these patients to developing OHSS. 
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OHSS affects a wide range of women of reproductive age; it is mainly 
characterized by an increase in VP which is mediated by the VEGF/VEGFR2 
system. Regulation of ovarian VEGF production, secretion, and action is 
dependent not only on exogenous gonadotropins but also on other factors, among 
them the D2 receptor.  
Research in murine tumor models (Basu S, et al, 2001) and in vitro studies in 
HUVECs (Human umbilical vein endotheial cells) (Sinha S, et al., 2009) have 
shown that administration of D2-ags can drastically reduce VP and angiogenesis. 
These studies suggested that activation of D2 on ECs exerts its effects on 
VEGFR2, inhibiting VEGF secretion and consequently reducing VP. Based on 
these findings, we hypothesized that the efficacy of D2-ags in decreasing VP may 
rely on the capacity of these drugs to inhibit VEGFR2 phosphorylation or VEGF 
secretion. This hypothesis suggests the existence of a dopaminergic system inside 
the ovary which determines the susceptibility of each woman to developing OHSS 
via VEGF/VEGFR2 system regulation.  
In this context, given the importance of VEGF in OHSS and because its regulation 
is mediated by Dp, we hypothesized that deregulation of the VEGF/VEGFR2 
pathway in women susceptible to OHSS, such as PCOS patients, might at least be 
partially due to abnormalities in the Dp/D2 system. In order to test the hypothesis 
outlined in this thesis, our main goal was to ascertain whether activation of the 
dopaminergic system is able to modulate the VEGF/VEGFR2 system in human 
LGCs, and to evaluate whether there were significant differences in the 
dopaminergic tone in healthy vs. PCOS patients which could explain their 
susceptibility to developing OHSS. 
We used an in vitro model consisting of LGCs isolated from FF in order to similate 
the in vivo CL luteinization process. Given that the FF is comprised of a 
heterogeneous cell population, it was necessary to establish an optised LGC 
isolation method in order to obtain adequate purity to culture these cells in vitro. 
 
DISCUSSION 
122 
 
To do this firstly we compared the efficiency of the different LGC cellular depletion 
and isolation methods already published. We noted that depletion strategies based 
on the physical properties of the contaminating and desired cells yeilded the 
highest percentage of viable LGCs but with high number of contaminating cells 
compared to other protocols. Methodologies based on immunological recognition of 
specific cell markers on contaminating cells provided acceptable levels of cellular 
purity and viability but a low number of LGCs, an obstacle which is especially 
critical when FF cannot be pooled because individual patients’ characteristics must 
be preserved. Therefore the number of in vitro assays which could be performed 
would have been unacceptably limited by the low number of LGCs yielded by this 
method. Finally, we decided to use a strain-filter isolation technique because it 
provided the highest number of LGCs and gave acceptable levels of purity without 
compromising the viability of the cells. Naturally, researchers that routinely use the 
aforementioned methods must generally obtain a more efficient recovery than ours.  
However we chose the strain-filter method to achieve our objectives in the in vitro 
studies. 
Once we found the best LGC isolation method, we focused our efforts in ascertain 
the potential role of the dopaminergic system in modulating angiogenesis through 
the VEGF/VEGFR2 pathway.  
 
Previous studies from our group hypothesized that the Dp/D2 system might be 
responsible for the decreases in ovarian VP observed in hyperstimulated rats 
(Gómez R, et al., 2006) as well as in women with a high risk of OHSS, when 
treated with D2-ags (Álvarez C, et al., 2007), and that this decrease might be due 
to a D2-ag mediated VEGFR2 phosphorylation blockade. Morevoer, this previous 
study in women with a risk of OHSS detected that they differentially express D2 on 
their ovarian ECs, leding us to hypothesize that this difference might explain the 
differences in the efficacy of D2-ags in preventing OHSS in some patients.  
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To date there is no consensus on the best dosage of D2-ags, however our study 
reported that VEGF secretion was decreased by D2-ags in a dose-dependent 
fashion. This result led us to think that previous observations by Shaltout A. et al., 
in a study with Cb2 in women with OHSS risk, in which low D2-ag doses can 
reduce the incidence of OHSS equally efficiently as high doses (Shaltout A, 2012) 
can probably be explained by the fact they only used low D2-ag doses; this would 
mean that they did not observe significant differences in VEGF secretion because 
low D2-ag doses are not as effective as high ones at inhibiting VEGF. Therefore, it 
is likely that the amount of dopaminergic signaling elicited in LGCs is the factor that 
determines VEGF inhibition. This observation supports the hypothesis that 
prevention of early OHSS might be improved by increasing the does of D2-ags 
administered to at-risk patients. This is in agreement with the findings of Busso et 
al. who demonstrated that high D2-ag doses were significantly more effective than 
lower doses in preventing early OHSS (Busso C, et al., 2010). 
Subsequently, we studied D2 modulation in order to evaluate the dopaminergic 
tone, establishing that the effect of D2-ags is mediated by the D2 receptor. 
Therefore, it is likely that dopaminergic signaling depends on D2 expression in 
LGCs. This finding led us to think that D2 expression in LGCs might be a factor 
determining the decrease in VEGF, hence, LGCs from some patients would be 
more efficient at inhibiting VEGF than others in response to the same D2-ag dose, 
depending on the amount of D2 expressed by these cells. 
To test this hyphotesis we explored if VEGF inhibition in response to fixed doses of 
D2-ags correlated with the amount of D2 expressed by LGCs in vitro. We observed 
a positive correlation between D2 and VEGF inhibition at low D2-ag doses because 
D2 expression on LGCs is the factor that determines differential VEGF secretion. In 
contrast, at high doses the excess D2-ag increases the probability of its binding to 
D2 so much that maximal VEGF inhibition is reached. Therefore, as D2 expression 
on the cell surface stops being a limiting factor in determining the dopaminergic 
stimuli, the correlation between D2 and the dopaminergic response disappears.  
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The immunohistochemical data we obtained that D2 expression was decreased 
during the late luteal phase. Assuming that our in vitro findings do indeed reflect 
the in vivo situation, we suggest that a low or decreased dopaminergic tone in 
human ovary, coinciding with the timing of the late luteal phase, causes the 
ineffectiveness of D2-ags in preventing OHSS. We speculated that due to low D2 
expression during late luteal phase, D2-ag doses administered to our patients in 
the past could not prevent late OHSS because these LGCs were not capable of 
producing the dopaminergic response necessary to sufficiently decrease VEGF. 
Therefore, we reasoned that the prevention and/or treatment of the onset of OHSS 
might be improved by increasing the intra-ovarian concentration of D2-ags by 
administering higher oral or vaginal doses. Moreover, intravenous treatment could 
be used if toxicity to high D2-ag doses becomes an issue, even in patients for 
whom the administrarion of low doses of D2-ags is insufficient to impede the early 
onset of OHSS.  
 
Once the role of the dopaminergic system in modulating angiogenesis through the 
VEGF/VEGFR2 system was ascertained, we aimed to understand whether there 
were significant differences in the dopaminergic tone between physiological and 
pathological conditions which could explain the particular susceptibility that PCOS 
patients have to developing OHSS. 
 
The findings presented in this thesis showed that PCOS women exhibit significantly 
lower D2 expression in theca and GCs and higher vascularization in the theca layer 
of antral and luteinized follicles compared to a non-PCOS group, consisting of 
women with a regular menstrual cycle. This observation agrees with the finding that 
VEGF is highly expressed in ovaries from PCOS patients (Kamat B, et al., 1995; 
Neulen J, et al., 1995; Agrawal R. et al., 2002) leading us to hypothesize that 
PCOS patients may express less D2 or that their D2 function might be deregulated 
which could induce elevated ovarian VEGF production and secretion compared to 
non-PCOS patients. 
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We expected our observations to show that PCOS women secrete more VEGF 
than non-PCOS women. Nevertheless, the results obtained suggested that the 
VEGF production and secretion by LGCs was similar in PCOS and non-PCOS 
patients. However, we observed less VEGF inhibition in PCOS vs. non-PCOS 
women in response to similar doses of D2-ags. This indicated that D2 was less 
efficient at decreasing VEGF in LGCs from PCOS than non-PCOS patients, so that 
higher doses of D2-ags are required to reach similar levels of VEGF inhibition in 
these patients. These results might be related to a low affinity of D2 to its ligand 
which would subsequently trigger high VEGF production in response to D2 
activation in PCOS patients. This idea is supported by the finding that the overall 
amount of VEGF secreted by LCGs from PCOS women is significantly higher than 
in non-PCOS women when they are stimulated with a higher D2-ag dose.  
 
In addition, our in vitro study reported that the Dp released by PCOS patient LGCs 
cultured with D2-ags was lower than that of non-PCOS women, indicating the 
existence of a deregulated dopaminergic tone in PCOS patients. Although LGCs 
do not synthetize Dp (Mayerhofer A, et al., 1998), these cells may be able to 
absorb Dp from the circulation, and store and metabolize it (Greiner M, et al., 
2008). Therefore the observed decrease in Dp secretion and an increase in the 
amout of DOPAC released is suggestive of an accelerated Dp metabolism in the 
CL of PCOS patients. The lower amount of Dp released by LGCs derived from 
PCOS led us to speculate that VEGF secretion could be regulated by the Dp-
mediated activation of D2, and that the ability of LGCs to reduce VEGF secretion 
might be limited in PCOS women. 
 
Based on the findings obtained in this study, we suggest that an accelerated Dp 
metabolism, as well as inefficient LGC D2 function leading to the poor inhibition of 
VEGF in PCOS patients, are the main causal factors in their increased 
susceptibility to develop OHSS. This is because the ovarian D2 present in these 
patients has an attenuated ability to inhibit VEGF secretion after D2-ag 
DISCUSSION 
126 
 
administration. This would also explain why the addition of exogenous D2-ags is 
expected to be less effective in preventing OHSS in PCOS women. 
The in vitro findings presented in this thesis suggested that the efficacy of D2-ags 
in preventing OHSS might be improved by increasing the intraovarian 
concentration of D2-ags. We are aware that results obtained from in vitro cultured 
LGCs can be criticized because they might not represent the in vivo ovarian 
environment; the validity of our data might also be criticized because of the high 
doses of D2-ags used in our in vitro study. Therefore, the application and 
therapeutic utility of these findings for the clinical management of patient disease 
must be further corroborated in in vivo studies.  
Although not included in this thesis, it is worth mentioning that we have also 
assayed the effect of D2-ags on ovarian VEGF secretion in our well-established 
and validated prl-supplemented OHSS animal model (Gómez R, et al., 2006). 
Although this work has not yet been published we can confirm that D2-ags inhibited 
VEGF protein production in the ovary in this model, thus supporting the 
assertations set out in this thesis.  
In summary, we sincerly hope that our findings will be helpful in improving 
knowlege of the regulation of VEGF/VEGFR2 by dopaminergic tone, as well as to 
help devise ways to better treat OHSS or related pathologies in which deregulated 
dopaminergic tone might lead to VEGF/VEGFR2-dependent pathologies. The 
findings obtained in the in vitro studies presented in this thesis led us to suggest 
the main conclusions detailed below.       
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1. FACS is the best protocol for isolating LGCs when purity is the principal 
requirement. Magnetic separation is the best option when both purity and 
viability are essential for subsequent experimentation. However, cell straining 
is probably the most efficient method with which to isolate LGCs as it offers the 
best combination of purity, viability, and cell recovery from all the 
methodologies currently available. 
 
2. D2 is consistently expressed in granulosa, theca, and immune cells throughout 
the luteal phase in the ovaries of all women. Therefore, the absence of this 
receptor in women who develop OHSS is not a plausible explanation for the 
differential efficacy of these drugs in preventing OHSS as had been previously 
hypothesized. 
 
3. D2 is not present on ovarian ECs, therefore, it is likely that D2-ags do not 
inhibit increases in ovarian VP by binding to D2 on ovarian ECs as we had 
previously hypothesized. 
 
4. The D2 staining intensity on LGCs decreases with the age of the CL to the 
point of nearly vanishing during the late luteal phase in all women. 
 
5. D2-ags decrease VEGF production and secretion by LGCs in vitro in a D2-
ag/D2-dependent manner.  
 
 
6. Unresponsiveness to the administration of D2-ags may be explained by the 
fact that low doses of D2-ags were used and because low levels of D2 
expression similar to those that characterize the late luteal phase also exist in 
the early luteal phase in some patients.  
 
7. The dopaminergic tone in the ovaries from patients suffering from PCOS is 
decreased when compared to regularly cycling women.  
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8. It is likely that D2-modulated changes in the VEGF/VEGFR2 pathway 
contribute to the typical vascular changes seen in PCOS ovaries and could 
explain why this group of women is at a higher risk of developing OHSS. 
 
9. We infer that the efficiency of dopaminergic therapies for OHSS treatment is 
likely to be improved by increasing the intra-ovarian concentration of D2-ags by 
administering higher oral or vaginal doses of these compounds. 
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